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 Abstract 
 
 
Rescue of inherited retinal degeneration associated with Aipl1 defects  
 
 
Cristy Ann Ku 
 
 
 Since groundbreaking clinical trials treating Leber congenital amaurosis (LCA) patients 
with retinal pigmented epithelium-specific 65 kDa protein (Rpe65) defects, which were the most 
successful gene therapy studies to date, much effort has been put into finding other candidate 
genes associated with inherited retinal degeneration to treat. Animal models with Rpe65 defects 
demonstrate an unusual circumstance that greatly favors treatment, where dramatic vision loss is 
disproportionately greater than the ensuing slow photoreceptor degeneration. This pattern is also 
believed to occur in Rpe65-LCA patients, and stems from the primary defect in retinal pigmented 
epithelial (RPE) cells that subsequently perturbs photoreceptors. However, a majority of 
inherited retinal degenerations are associated with photoreceptor gene defects, and do not show 
this advantageous disparity between visual dysfunction and photoreceptor loss. To combat this, 
efforts have concentrated on improving photoreceptor transduction efficiency with viral vectors, 
and delivering gene replacement to slower progressing retinal dystrophies.  
 Aryl hydrocarbon receptor interacting protein-like1 (Aipl1) is mainly associated with the 
severe retinal degeneration, LCA. However, reports of Aipl1 defects in patients showing slower 
progressing retinal disease, retinitis pigmentosa (RP) and cone-rod dystrophy (CORD), points to 
a subset of Aipl1 patients as potential candidates for future AAV-mediated gene therapy trials. 
Multiple mouse models with Aipl1 defects have been developed and contribute to the ease of 
conducting pre-clinical rescue studies to examine the rescue potential of Aipl1.  
 To investigate the rescue potential of Aipl1 defects, we conducted AAV-mediated gene 
replacement studies in Aipl1-null mice, a model for Aipl1-LCA, the most rapidly progressing of 
any retinal degeneration mouse model. Our study examines the recent advancements in AAV 
viral vectors, using a combined self-complementary Y733F capsid mutant AAV8 (sc-Y733F-
AAV8), to evaluate whether these advancements would provide functional benefits to a model of 
retinal degeneration. We found that the sc-Y733F-AAV8 viral vector significantly improved 
vision rescue in Aipl1-null mice as compared to conventional single-stranded AAV8, even when 
treatment was administered at postnatal day 10, after initiation of photoreceptor degeneration. 
From these studies, we also conclude that the Aipl1-null mouse provides a good model to test the 
functional benefits of ongoing and future advancements in AAV viral vectors.  
 In addition to LCA, Aipl1 has been reported in patients with CORD and RP. We were 
particularly interested in a mutation, P351Δ12 hAipl1 because of its association with CORD and 
our ongoing interest in the role of Aipl1 in cone photoreceptors. We generated a transgenic 
mouse model expressing P351Δ12 hAIPL1, which showed a cone-rod dystrophy phenotype 
similar to a case of Aipl1-CORD in a patient with this mutation. The mice demonstrated early 
and rapidly declining cone-mediated vision with slow progressing rod defects. Additionally, in 
our studies of double transgenic mice expressing both mutant P351Δ12 hAIPL1 and WT 
hAIPL1, we conclude that the P351Δ12 hAipl1 mutation does exert dominant effects that explain 
the autosomal dominant inheritance pattern observed in the Aipl1 patients with this mutation. 
 Interestingly, despite the dominant phenotype, we were able to rescue cone dysfunction and 
degeneration following AAV-mediated gene delivery of WT hAIPL1. We believe this is due to 
the drastic overexpression of WT hAIPL1 that is achieved with AAV gene delivery. Further 
work with this novel model of Aipl1-CORD is needed to elucidate the dominant mechanism of 
the P351Δ12 hAIPL1 protein, which appear to behave differently in rods and cones, as rod 
dysfunction was not rescued with AAV-mediated overexpression of WT hAIPL1. With these 
successes in pre-clinical Aipl1 rescue studies, which have also been independently demonstrated 
by two other groups, we conclude that Aipl1 defects show great potential for movement into 
AAV-mediated gene therapy clinical trials. 
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Chapter 1 
 
Literature Review 
 
Significance: Inherited retinal degenerations (IRD) 
Hereditary retinal degeneration is a major cause of blindness affecting an estimated 1 in 
3000 people (Wright et al., 2010). However, it is actually comprised of a diverse group of 
blinding diseases that exhibit a spectrum of presenting symptoms and severity, with varied onset 
and progression of vision loss. Leber congenital amaurosis (LCA) is the most severe of inherited 
retinal degenerations (IRD), characterized by severe visual impairment within the first few 
months of life and extinguished or severely reduced rod- and cone-mediated electroretinograms 
(ERGs) (Schappert-Kimmijser et al., 1959; Foxman et al., 1985). Relative to LCA, retinitis 
pigmentosa (RP) and cone-rod dystrophy (CORD) are less severe along the IRD spectrum, 
showing later onset and slower progression to complete vision loss. RP patients present with 
night blindness as the first visual impairment alongside normal visual acuity. In contrast to RP, 
CORD patients initially present with decreased visual acuity, central vision loss, and 
dyschromotopsia with progressive loss of peripheral, rod-mediated vision. Visual defects and 
subsequent retinal degeneration stem from improper splicing, nonsense, or missense genetic 
mutations translating altered, dysfunctional, or non-functional proteins whose normal function is 
essential in photoreceptors or retinal pigmented epithelium (RPE).  
While historically untreatable, recent breakthroughs in pre-clinical and clinical gene 
replacement therapy trials have led to the potential to treat retinal dystrophies. Specifically, 
adeno-associated virus (AAV)-mediated gene therapy for LCA due to retinal pigment 
epithelium-specific 65 kDa protein (Rpe65) gene defects showed therapeutic effects in phase I 
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clinical trials (Bainbridge et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Jacobson et 
al., 2012)  with ongoing phase II/III clinical trials (ClinicalTrials.gov, January 15, 2011). Rpe65 
clinical trials are one of the most successful examples of gene therapy to date in safety and 
efficacy, leading to a push for treating inherited retinal dystrophies linked to other causative 
genes. An inherent challenge, however, is the multitude of associated genes implicated within 
even a single inherited retinal degenerative disease, such as retinitis pigmentosa (RP) associated 
with defects in over 50 genes, and the more severe Leber congenital amaurosis (LCA) associated 
with defects in 16 genes (RetNet, http://www.sph.uth.tmc.edu, November 15, 2011). A majority 
of these are photoreceptor genes (RetNet), making targeting of photoreceptor defects an 
important next step in ocular gene therapy.  
Aipl1 is one photoreceptor gene demonstrating potential for entry into clinical trials. 
Aipl1 defects are associated mainly with autosomal recessive LCA, making up 7% of LCA cases 
(Sohocki et al., 2000b). Additionally, Aipl1 defects are associated with RP and CORD in select 
cases, pointing to a subset of Aip1l patients with a larger window of opportunity for treatment 
relative to Aipl1-LCA patients. Multiple Aipl1 mouse models allow for pre-clinical testing of the 
rescue potential of Aipl1 associated IRDs. Two independent Aipl1-null mouse models phenocopy 
LCA, and demonstrate the most rapid photoreceptor degeneration in any mouse model of retinal 
degeneration. Aipl1-null mice not only provide a uniquely suited model for testing the efficiency 
of viral vectors, but also proof-of-concept that less severe retinal degenerations may successfully 
be treated if the most severe of retinal degenerations is rescued. Aipl1 hypomorph mice with a 
75-80% reduction in protein levels, and our novel transgenic mouse expressing patient mutation 
P351Δ12 hAipl1 offer models of Aipl1-RP and -CORD, which may better predict the rescue 
capacity of Aipl1 associated with less severe non-LCA IRDs. 
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Retinal and retinal pigmented epithelium (RPE) defects in IRD 
The neural retina is a laminated structure with three cellular layers, the outer nuclear 
layer (ONL), the inner nuclear layer (INL), and the retinal ganglion cell (RGC) layer (Fig. 1A). 
Rod and cone photoreceptors, which make up the ONL of the neural retina, have three distinct 
cellular compartments (Fig. 1A). Photoreceptor outer segments (OS) are membranous discs that 
house essential phototransduction proteins. OS are shed and regenerated daily to negate the toxic 
effects of accumulated photo-oxidative products (Kevany and Palczewski 2010). Inner segments 
(IS) house the cellular machinery for synthesis of proteins, including outer segment proteins 
which are transported from the IS to OS via a connecting cilia (CC). The last photoreceptor 
compartment, the synaptic terminal, is the site of glutamate release which signals to secondary 
neurons in the INL. Visual transduction then propagates to the tertiary RGCs, the axons of which 
converge and form the optic nerve, feeding information to the visual cortex.  
The non-neural RPE, located between photoreceptors and the vascular choroid (Fig. 1A), 
plays essential roles in the health and maintenance of photoreceptors. The RPE functions to 
absorb excess light, transport nutrients and ions to the retina from the choriocapillaries, and 
provide anti-oxidant and repair functions against high photo-oxidation occurring in the eye 
(Kevany and Palczewski 2010). Additionally, it serves two vital functions associated with retinal 
degeneration when awry: phagocytosis of shed photoreceptor outer segments; and production of 
visual retinoid 11-cis retinal, necessary for generating photoactivatable opsins (Fig. 1B). 
Mutations in the RPE gene, Mertk (c-mer proto-oncogene receptor tyrosine kinase), lead 
to defective OS phagocytosis due to a lack of signaling for OS ingestion (Feng et al., 2002), and 
is associated with retinitis pigmentosa (RetNet) and modeled by the Royal College of Surgeons 
(RCS) rat. Defects in four RPE genes involved in the visual retinoid cycle are associated with 
4 
 
IRD (Fig. 1B, Fig. 2) (RetNet). Lrat (lecithin retinol acyltransferase), Rdh12 (retinal 
dehydrogenase 12), and Rpe65 (retinal pigmented epithelium-specific 65 kDa protein), the 
genetic mutation currently treated in gene therapy clinical trials, are all associated with both RP 
and LCA. Rdh5 (retinal dehydrogenase 5, or cis-RDH in Fig. 1B) is associated with CORD. 
Photoreceptor gene defects are more numerous in their mechanisms of disease. Broad 
mechanisms of dysfunction include, but are not all-inclusive to the following: retinal 
development/retinal cell fates and structure, phototransduction cascade, photoreceptor OS 
structure, and protein transport across the connecting cilium (Fig. 2). Photoreceptor genes make 
up the majority of genetic defects, as compared to the four RPE genes, associated with IRD (Fig. 
2). However, prior to recent advancements in AAV, transduction of the neural retina with viral 
vectors was highly inefficient. In contrast, early viral-mediated ocular gene therapy demonstrated 
robust RPE transduction. We first discuss the early developments in AAV-mediated gene 
delivery coupled with in vivo characterization of Rpe65 defects that led to the successful 
translation into Rpe65 clinical trials. Subsequently discussed are the recent advancements in viral 
vectors allowing for efficient photoreceptor transduction, and the potential for treatment of the 
photoreceptor gene, Aipl1. 
 
Ocular viral gene therapy 
Early ocular viral gene therapy studies, development of AAV 
Attempts at ocular gene replacement therapy started in the mid 1990s, however, initial 
use of adenoviral (Ad) vectors resulted in inefficient transduction of neural retinal cells and 
limited duration of gene expression (Bennett et al., 1994; Jomary et al., 1994; Li, T. et al., 1994; 
Li, T. and Davidson 1995; Ali et al., 1997; Wright 1997). Even in an immune privileged site of 
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the eye, expression decreased by 3-4 weeks post-injection due to immune responses against viral 
proteins (Li, T. et al., 1994; Reichel et al., 1998). Re-administration of Ad accelerated loss of 
expression, whereas expression was prolonged in immunodeficient nude mice, further 
confirming that immunogenicity hinders effective use of Ad (Reichel et al., 1998). In contrast, 
early studies using recombinant adeno-associated viral (rAAV) vectors showed distinct 
advantages in greater safety, photoreceptor transduction and expression duration (Ali et al., 
1996; Ali et al., 1997; Flannery et al., 1997; Jomary et al., 1997; Wright 1997).  
Adeno-associated virus (AAV) is a linear single-stranded DNA virus belonging to the 
Parvoviridae family and the Dependovirus genus. As implied by its name, AAV was originally 
found as a contaminant in a preparation of simian adenovirus. There, it was characterized as 
replication defective, requiring a helper virus such as adenovirus to replicate (Atchison et al., 
1965). AAV is non-pathogenic in humans and 40-80% of adults are seropositive for AAV 
without associated symptoms or disease (Sprecher-Goldberger et al., 1971). AAV shows low 
immunogenicity which is attributed to its lack of transduction and/or activation of antigen-
presenting cells (APCs) (Jooss et al., 1998). 
Cloning of the prototypic AAV2 into a bacterial plasmid was the first step of developing 
AAV as a vector and gene transduction system (Samulski et al., 1982; Hermonat and Muzyczka 
1984). Recombinant AAV vectors devoid of all viral genes except for two inverted repeats 
(ITRs) between which the transgene of choice is cloned, further decreased immunogenicity by 
eliminating generation of wildtype AAV (Samulski et al., 1989). Rather, a helper plasmid which 
encodes AAV rep and cap genes necessary for AAV replication and viral capsid assembly, 
respectively, are supplied in trans alongside infection with helper Ad during rAAV vector 
production (Fig. 3), which are subsequently removed during purification.  
6 
 
Although wildtype AAV can integrate into the human genome at chromosome 19q13.3-
qter (Kotin et al., 1991; Samulski et al., 1991), it requires AAV rep proteins which mediate 
complex formation at a sequence-specific integration site (Weitzman et al., 1994). Recombinant 
AAV vectors exist predominantly as non-integrated episomes in postmitotic cells (Muzyczka et 
al., 1984; Duan et al., 1998; Schnepp et al., 2003; Penaud-Budloo et al., 2008; Schultz and 
Chamberlain 2008; Clark and Penaud-Budloo 2011) likely due to an absence of rep proteins in 
final rAAV vector preparations. Integration was however induced into double-stranded break 
sites following administration of DNA damaging agents (Miller et al., 2004).  
As mentioned, adenovirus (Ad) is immunogenic and pathogenic, posing problems in 
production of AAV which required helper Ad for replication. Contaminating helper Ad in in vivo 
AAV-mediated gene delivery elicited cellular immune responses (Mccoy et al., 1995; Monahan 
et al., 1998). In addition to problematic in vivo humoral responses, presence of contaminating 
helper Ad hindered effective production of purified high-titer recombinant AAV.  
 
Production of high-titer purified AAV 
Several important developments have contributed to the capacity to produce high-titer 
purified AAV. First, greater understanding of the role of helper Ad in enhancement of 
transcription and translation of AAV rep and cap genes and second-strand synthesis during AAV 
replication (Jay et al., 1981; Richardson and Westphal 1984; Samulski and Shenk 1988; Chang et 
al., 1989; Janik et al., 1989; Ferrari et al., 1996), led to the development of a helper plasmid that 
encodes necessary Ad genes (Ferrari et al., 1997; Grimm et al., 1998; Xiao et al., 1998) (Fig. 3). 
This not only eliminated the need for infection with Ad and subsequent problems in purification 
of contaminating Ad, but also improved rAAV yields over 40-fold. This was attributed to a 
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controllable amount of helper Ad gene products, and freeing up of biochemical machinery since 
Ad helper plasmids do not lead to Ad virus packaging and replication (Xiao et al., 1998). 
Secondly, optimization of AAV rep and cap protein expression involved in replication and 
packaging improved yields (Grimm et al., 1998; Xiao et al., 1998; Collaco et al., 1999), as rep 
overexpression was found to limit capsid assembly (Fan and Dong 1997; Li, J. et al., 1997).  
Lastly, novel purification methods such as heparin affinity chromatography for AAV2 
(Clark et al., 1999), and iodixanol gradient centrifugation followed by anion-exchange 
chromatography for all AAV serotypes (Zolotukhin et al., 2002; De Backer et al., 2011) has 
replaced inefficient cesium chloride (CsCl) gradient centrifugation purification. Multiple CsCl 
gradient centrifugations needed for in vivo rAAV preparations led to low yields and lack of 
scalability. Moreover, aggregation of rAAV with Ad cellular proteins occurred in the presence of 
CsCl, and toxicity of CsCl necessitated extensive dialysis post-centrifugation (Burova and Ioffe 
2005). Iodixanol centrifugation, in comparison, eliminated aggregation of macromolecules and 
did not require dialysis prior to subsequent chromatography purification (Zolotukhin et al., 
1999). Most importantly, rAAV vector preparations showed superior viral infectivity following 
iodixanol compared to CsCl gradient purification (Zolotukhin et al., 1999).  
 
Transduction of retinal pigmented epithelial (RPE) cells 
 The RPE is highly permissible for viral transduction which was achieved even in early 
studies using Ad (Jomary et al., 1994; Li, T. et al., 1994; Li, T. and Davidson 1995). However, 
immunogenicity and subsequent transient expression in RPE cells limited the in vivo use of 
adenoviral gene vectors (Li, T. et al., 1994; Reichel et al., 1998). The prototypic AAV2 showed 
efficient transduction and a greater safety profile than Ad (Ali et al., 1996; Grant et al., 1997). 
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More importantly, longevity of expression was demonstrated up to 11 weeks post-injection 
(Bennett et al., 1997).  
Cloning and characterization of additional AAV serotypes led to development of 
pseudotyped AAVs, where rAAV vectors express AAV2 rep proteins with cap proteins of a 
different AAV serotype. All AAV serotypes (AAV1-9) developed thus far have demonstrated 
efficient RPE transduction, with AAV2, 4, and 6 primarily transducing RPE over neural retina 
(Lebherz et al., 2008; Beltran 2009; Boye, S. E. 2012). Ultimately, ease of RPE transduction led 
to specific targeting of Rpe65 LCA patients for clinical trials and contributed to the success of 
these trials.  
 
Gene therapy for Rpe65 LCA: From pre-clinical to clinical trials 
RPE65 plays a role in the production of visual chromophore 11-cis retinal necessary for 
regeneration of photoactivatable rhodopsin (Redmond et al., 1998). Specifically, RPE65, an 
isomerase present in the retinal pigmented epithelium, converts all-trans retinyl esters into 11-cis 
retinyl esters (Fig. 1B). In LCA2, the primary defect is in RPE65, leading to dysfunctional 
rhodopsin and phototransduction signaling. Photoreceptors show subsequent but delayed 
degeneration, relative to early visual dysfunction in Rpe65-null mice and dogs. In Rpe65-null 
mice, initial morphological abnormalities are observed at 7-15 weeks of age with outer segment 
disorganization. Slow progressive loss of photoreceptors ensues with 70% of ONL remaining at 
6-7 months, 50% of the ONL at 12-18 months, and 30% at 24 months of age (Redmond et al., 
1998; Gouras et al., 2002; Cideciyan 2010). Although significant photoreceptor loss does not 
occur until about 12-18 months of age, ERG responses are abolished at 10 weeks of age 
(Redmond et al., 1998). A similar trend is present in the Rpe65 Briard dog, where a naturally 
9 
 
occurring homozygous 4-bp frameshift deletion was found. This mutation introduces a premature 
stop codon that truncates two-thirds of the protein resulting in a nonfunctional protein (Veske et 
al., 1999). At 5 weeks of age, Rpe65 dogs demonstrate abolished scotopic ERG responses and 
low photopic responses despite a near normal retina with some outer segment disorganization 
(Narfstrom et al., 2003). Photoreceptor cell loss begins at 7-18 weeks of age and is complete by 7 
years of age in the peripheral retina (Wrigstad et al., 1992; Wrigstad et al., 1994; Hernandez et 
al., 2010). These results show that in young Rpe65 mice and dogs, photoreceptor loss does not 
correlate with the observed level of visual function loss (Cideciyan 2010).  
This observation was confirmed with a mathematical model that predicts photoreceptor 
function proportional to the product of the number of surviving photoreceptors and the length of 
their outer segments in retinal degeneration (Machida et al., 2000), or approximately as the loss 
of light sensitivity (in linear units) proportional to the square of ONL thinning (Jacobson et al., 
2005). In line with Rpe65 animal models, in vivo optical coherence tomography (OCT) studies of 
Rpe65 LCA patients show areas of partially retained photoreceptors averaging about 60-65% of 
normal photoreceptor thickness, which is greater than expected for the level of dysfunction at 
both the fovea and rod-rich regions (Jacobson et al., 2005; Cideciyan 2010). In comparison, OCT 
data from non-Rpe65 retinal degeneration patients demonstrated that photoreceptor loss was in 
line with loss of visual function (Jacobson et al., 2007b; Jacobson et al., 2008a). This 
characteristic of Rpe65 defects provides a therapeutic window of opportunity that led to 
successful vision rescue in Rpe65 animal models and indicated Rpe65 LCA patients as good 
candidates for gene therapy clinical trials. 
Vision restoration was achieved with multiple AAV serotypes in the Rpe65-null mouse. 
Treatment with AAV1 at 2 months of age or earlier led to a high success rate and restoration of 
10 
 
ERG a- and b-waves, whereas treatment at 1.5 to 2 years of age led to a low success rate and 
restoration only of b-waves (Jacobson et al., 2005). In utero AAV1 treatment led to equal or 
greater rescue of ERG responses than treatment at 2 months of age (Dejneka et al., 2004). These 
studies indicate that early intervention benefits vision rescue even in Rpe65 slow degeneration. 
Rescue of Rpe65-null mice was also achieved with AAV2 (Bennicelli et al., 2008), the serotype 
primarily used in rescue of the Rpe65 canine model. Fully functional vision rescue was achieved 
in the Rpe65 canine model as measured through 11-cis retinal regeneration, ERGs, pupillary 
light responses, cortical activity, and vision-guided navigation following treatment at 3-5 months 
of age (Acland et al., 2001; Aguirre et al., 2007), with stability of rescue up to 3 years post-
injection (Acland et al., 2005). Safety of AAV2-Rpe65 in nonhuman primates was also 
demonstrated prior to advancement into clinical trials (Jacobson et al., 2006). 
Three independent phase I clinical trials demonstrated patient safety following delivery 
of AAV2-RPE65 to young adult Rpe65-LCA patients, with no significant occurrence of humoral 
responses nor presence of viral vectors in saliva, tears, or peripheral blood (Bainbridge et al., 
2008; Hauswirth et al., 2008; Maguire et al., 2008). More importantly, the studies demonstrated 
treatment efficacy in multiple measurements of visual function. In one study, 3 of 3 patients 
showed improved visual acuity that lasted at least 1.5 years post-treatment (Maguire et al., 2008; 
Maguire et al., 2009). Despite unimproved visual acuity in the other two studies, improvements 
in vision were observed through more sensitive visual function assays. Treated eyes 
demonstrated improved light sensitivity as measured through full-field sensitivity tests 
(Hauswirth et al., 2008; Maguire et al., 2009), a psychophysical test designed to assay vision in 
patients with severe vision loss (Roman et al., 2007). Secondly, transient pupillary light reflex 
(TPLR) responses which demonstrate transmission of visual information from the retina to the 
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brainstem, were elicited at lower light intensities post-treatment than at baseline, demonstrating 
enhanced light sensitivity (Cidecian et al., 2008; Maguire et al., 2008, 2009). Three year post-
treatment follow-up showed that patients also interestingly developed a pseudofovea, an 
extrafoveal area with improved visual acuity and light sensitivity that therefore functioned as a 
central fixation locus (Jacobson et al., 2012).  
 
Advancements in AAV for photoreceptor targeting 
Rapid and efficient transduction of photoreceptors  
 Although first generation AAV2 provide high transduction of retinal pigmented 
epithelium in Rpe65 clinical trials, AAV2 shows limited transduction of photoreceptors (Grant et 
al., 1997; Ali et al., 1998). Greater photoreceptor transduction has been achieved with AAV5, 7, 
and 8 over AAV2 (Yang et al., 2002; Allocca et al., 2007; Lebherz et al., 2008). The standout 
pseudotype for photoreceptor targeting has been AAV8 following its isolation from the rhesus 
monkey (Gao et al., 2002). AAV8 demonstrated greater photoreceptor transduction at early post-
injection times, as rapid as 5 days post-injection compared to 1-2 weeks post-injection in AAV2 
and 5. Additionally, at the plateau of expression, AAV8 provided significantly higher 
photoreceptor transduction than AAV5 (Natkunarajah et al., 2008). AAV7 demonstrated slightly 
higher or similar photoreceptor transduction to AAV8 at 4-5 weeks post-injection (Allocca et al., 
2007; Lebherz et al., 2008), although early photoreceptor transduction has not been examined. 
The robust and rapid kinetics of photoreceptor transduction has set AAV8 apart from other 
recent AAV serotypes, providing an essential characteristic for rapid retinal degeneration often 
seen with photoreceptor gene defects. While AAV7 and 8 provide a clear advantage in 
photoreceptor tropism, the route of viral particle binding and entry has not been elucidated for 
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these serotypes. In contrast, it is known that AAV2 binds heparan sulfate and AAV5 sialic acid 
as the primary receptor for attachment (Summerford and Samulski 1998; Walters et al., 2001). 
Elucidating the receptor for AAV7 and 8 may shed light on the high photoreceptor tropism and 
potential methods to enhance photoreceptor targeting.  
Early onset of expression is also achieved with self-complementary AAV (scAAV), 
which forms a double-stranded DNA (dsDNA) conformation that bypasses second-strand 
synthesis required by conventional single-stranded AAV (ssAAV) prior to transcription. scAAV 
is generated by mutating the terminal resolution site (trs) in the 5’ ITR in the wildtype AAV 
construct, which leads to read-through and formation of a dimeric inverted repeat structure with 
two complete ITRs at the ends and a mutated ITR in the middle during replication (Mccarty et 
al., 2001; Mccarty et al., 2003; Mccarty 2008) (Fig. 4). Expression initiates as early as post-
injection (pi) day 2-3 with scAAV8 and scAAV2, as compared to pi day 5-7 in ssAAV8 and pi 
day 14 in ssAAV2 (Yokoi et al., 2007; Natkunarajah et al., 2008). In addition, scAAV provided 
higher transduction efficiency over ssAAV for AAV2, 5, and 8, at 5 weeks post-injection when 
maximal transduction has occurred (Yokoi et al., 2007; Natkunarajah et al., 2008). The increased 
efficiency of scAAV is partially attributed to degradation of ssAAV during the single-stranded 
phase. Further characterization of ss- and scAAV processing is needed however, as opposing 
studies report a transient instability of both ssAAV and scAAV following cell entry (Mccarty 
2008). 
Another advancement that improves stability of viral particles upon cell entry is AAV 
capsid mutations. Studies examining intracellular trafficking of rAAV revealed that 
ubiquitination and proteasomal degradation of viral particles was one route of decreased 
transduction efficiency (Yan et al., 2002; Zhong et al., 2007; Zhong et al., 2008a). Since 
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ubiquitination of cellular and viral proteins is often modulated through phosphorylation of serine 
and tyrosine residues, mutagenesis of surface-exposed tyrosine residues of capsid proteins were 
reasoned to protect against viral particle degradation. As hypothesized, tyrosine capsid mutants 
showed greater transduction over their wildtype capsid counterparts (Petrs-Silva et al., 2009; 
Ryals et al., 2011). Recently developed threonine capsid mutations are also showing similar 
effects to tyrosine mutations (Boye, S.E. 2012).  
 
Current limitations in AAV-mediated gene therapy 
 Despite advantages in the safety and efficacy of AAV, some limitations remain with its 
use. The greatest hindrance is the limitation in transgene size of 4.7 kb for single-stranded AAV 
and 2.3 kb for self-complementary AAV. This size restriction, which must include both gene 
promoter and transgene, stems from the natural size of the wildtype AAV genome between two 
inverted terminal repeats (ITRs). It prevents delivery of LCA gene Cep290 (7.4 kb), and scAAV 
packaging of Crb1 (4.2 kb), Gucy2d (3.3 kb), and Rpgrip1 (3.8 kb). Attempts at pushing beyond 
the packaging capacity showed that above 5.2 kb, vector genomes were truncated at the 5’ end 
(Dong et al., 2010; Wu, Z. et al., 2010). A slight improvement to 6.0 kb was obtained by 
eliminating the VP2 capsid protein, one of three capsid proteins normally needed for viral 
encapsulation (Grieger and Samulski 2005). In contrast to these studies, one group demonstrated 
intact viral genome packaging and in vivo transduction of an 8.9 kb transgene with AAV5 
(Allocca et al., 2008). Despite this controversy, the packaging capacity of AAV is in stark 
contrast to the 36 kb capacity of Ad (Beltran 2009). 
 Another limitation in AAV retinal gene therapy is the cumbersome and delicate 
administration of viral solution into the subretinal space (Fig. 5), which is actually a non-
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physiological potential space between the retina and RPE. In patients, the procedure requires a 
vitrectomy followed by a puncture through the retina (retinotomy). In addition to transient 
detachment and local damage of the retina, disadvantages of subretinal injection into patients 
with retinal degeneration are two-fold. First, non-uniform degeneration makes it difficult to 
identify the best area to introduce the virus. Secondly, the degenerating retina is extremely 
fragile and susceptible to retinal tears (Maguire et al., 2008).  
In contrast, intravitreal injection (Fig. 5) is a safe and relatively easy outpatient procedure 
routinely conducted to deliver anti-VEGF drugs to wet AMD patients. Although transduction of 
retinal ganglion cells following intravitreal injections have been demonstrated with AAV2, 8, 
and 9 (Harvey et al., 2002; Lebherz et al., 2008; Giove et al., 2010; Yin et al., 2011), efficient 
transduction of outer retinal photoreceptors is hindered by the inner limiting membrane (ILM) 
(Dalkara et al., 2009). The ILM is a basement membrane composed of various extracellular 
matrix proteins, several of which have been found to mediate AAV2, 8, and 9 binding and 
accumulation at the vitreoretinal junction (Akache et al., 2006; Kolstad et al., 2010). The ILM is 
essential in retinal development but is dispensable in adults, as its removal is commonly 
conducted in macular hole surgeries. Importantly, this barrier was partially overcome with co-
administration of proteolytic enzymes with AAV, a potential therapeutic application for 
transducing the outer retina via an intravitreal injection (Dalkara et al., 2009). However, further 
progress is needed to improve upon the efficiency of outer retinal transduction achieved in this 
study. Another advancement found to transduce photoreceptor following intravitreal delivery is 
AAV triple tyrosine capsid mutant, which interestingly transduced foveal cone photoreceptors in 
non-human primates (Boye, S.E. 2012). This is a particularly desirable development as foveal 
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thinning was a complication in several Rpe65 LCA patients receiving viral gene therapy, likely 
arising from foveal detachment following subretinal injections (Jacobson et al., 2012).  
 
Targeting photoreceptor gene defects: Aipl1 as a candidate gene 
Overview 
 Since Rpe65 LCA clinical trials, there has been a push to target additional genetic defects 
associated with inherited retinal degeneration. Recent and continuing advancements in AAV 
vectors improved photoreceptor transduction, allowing for correction of photoreceptor defects. 
Treatment of defects in Aipl1, a chaperone protein for the phototransduction protein 
phosphodiesterase 6 (PDE6), shows potential for entry into clinical trials. Although Aipl1 is 
mainly associated with LCA, the most severe of IRDs, it has also been linked to CORD and RP 
which show later onset and slower progression of vision loss (Fig. 7), indicating a subset of Aipl1 
patients who can benefit from gene replacement therapy. 
Multiple Aipl1 mouse models exist allowing for pre-clinical gene therapy studies. The 
Aipl1-null mouse models Aipl1-LCA, whereas the Aipl1 hypomorph mouse, with a 75-80% 
reduction in protein levels, models a slow progressing retinal degeneration. Additionally, our 
novel P351Δ12 Aipl1 mutant mouse phenocopies Aipl1-CORD. Successful vision rescue 
following AAV-mediated gene replacement was achieved in several of these mouse models, 
showing the potential to correct IRDs associated with Aipl1 defects.  
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Aryl hydrocarbon receptor interacting protein-like 1 (Aipl1) defects 
Aryl hydrocarbon receptor interacting protein-like 1 (AIPL1) is a 384 aa protein found in 
the pineal gland and retina, where it is specifically expressed in early and mature rod and cone 
photoreceptors (Van Der Spuy et al., 2003; Kirschman et al., 2010). AIPL1 is a member of the 
immunophilin FK506 binding protein (FKBP) family. Similar to several multi-domain 
immunophilins, AIPL1 contains an N-terminal peptidyl-prolyl cis-trans isomerase (PPIase)-like 
domain and three C-terminal tetratricopeptide repeat (TPR) domains. Primate AIPL1 isoforms 
also contain a C-terminal proline-rich region referred to as the hinge region, an area of unknown 
function or significance (Fig. 6A).  
Aipl1-null and hypomorphic mice, which express 20-25% of wildtype AIPL1 levels (Liu 
et al., 2004), show a specific and dramatic reduction of all rod PDE subunits despite unaltered 
mRNA levels (Liu et al., 2004; Ramamurthy et al., 2004), indicating the role of AIPL1 in post-
transcriptional processing of rod PDE6 holoenzyme. Further work has elucidated that AIPL1 is 
required for the stability of rod PDE6 subunits and assembly of the PDE6αβγ2 complex, and that 
AIPL1 specifically interacts with the α catalytic subunit (Kolandaivelu et al., 2009). The 
interaction between AIPL1 and PDEα subunit is not surprising due to yeast two-hybrid studies 
showing the interaction of AIPL1 with farnesylated proteins (Ramamurthy et al., 2003). 
However, whether AIPL1 acts to facilitate the farnesylation reaction of PDEα, folding of PDEα 
or oligomerization of PDE6αβγ2 remains unknown, all of which may enhance PDE6 stability and 
assembly. The site of PDEα interaction for AIPL1 chaperone activity has also yet to be 
elucidated. The role of AIPL1 in cone photoreceptors is currently being elucidated, as loss of 
AIPL1 leads to rapid rod and cone degeneration associated with LCA and modeled in the Aipl1-
null mouse. Loss of cone photoreceptors is not simply secondary to massive rod loss, as 
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demonstrated by the cone-specific elimination of AIPL1 leading to loss of photopic ERGs and 
cone death (Kirschman et al., 2010).  
Defects in Aipl1 are associated with autosomal recessive Leber congenital amaurosis 
(LCA4), in approximately 7% of LCA cases (Sohocki et al., 2000b). Several reports also link 
Aipl1 defects to autosomal dominant cone-rod dystrophy (adCORD), juvenile retinitis 
pigmentosa (RP), non-early onset RP, and later onset retinal degeneration (Sohocki et al., 2000b; 
Vallespin et al., 2007; Walia et al., 2010; Jacobson et al., 2011) (Fig. 6C, Fig. 7).  
LCA is the most severe of retinal degenerations, with severe visual impairment within the 
first few months of life and absent or severely reduced rod- and cone-mediated ERGs. RP 
patients typically present with night blindness as the first visual impairment alongside normal 
visual acuity, with somewhat varied progression and severity. Although clear diagnostic criteria 
are not universally agreed upon, juvenile, early- or childhood-onset RP typically denote 
symptoms initiating from 1 year to 10 years of age, whereas non-early or late-onset RP typically 
refers to initiation after 10 years of age. CORD patients present with impaired central vision and 
decreased visual acuity with progressive loss of peripheral vision, but retain measurable ERGs 
for several years. The case of Aipl1 associated with later onset retinal degeneration was 
described with slower onset and progression than LCA or juvenile RP (Jacobson et al., 2011). 
These cases of non-LCA IRDs associated with Aipl1 (Fig. 6C) indicate a larger window of 
opportunity for treatment relative to Aipl1-LCA. Additionally, evidence of ERG responses and 
photoreceptor survival in some Aipl1 patients demonstrate salvageable photoreceptor cells (Fig. 
6C) (Jacobson et al., 2011; Pennesi et al., 2011; Testa et al., 2011). 
The most common Aipl1 defect in over 60% of Aipl1-LCA cases is truncation mutation 
W278X (Dharmaraj et al., 2004; Hanein et al., 2004) leading to an unstable and degraded protein 
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(Ramamurthy et al., 2003), which is mimicked in the Aipl1-null mouse model. However, point 
mutations and small base pair deletions in the PPIase-like and TPR domains of AIPL1 are also 
prevalent in the patient population. Several point mutations such as A197P and C239R retain 
functionality in vitro in interacting with and processing farnesylated proteins despite 
compromised folding and stability (Ramamurthy et al., 2003). Whether some mutations translate 
functional or partially functional protein is an important clinically relevant question. The Aipl1 
hypomorphic mouse mimics such a hypothetical state. In addition, a reported patient mutation 
P351Δ12 in the C-terminal proline-rich hinge region retains partial functionality in vivo as 
demonstrated in our hAipl1 transgenic mouse model (Chapter 3). Although the rarity of Aipl1 
cases severely limits any genotype-phenotype correlations that can be made, reports of Aipl1 -
CORD and -RP (Fig. 6C), combined with the idea that some mutations may retain functionality, 
indicate the potential of a subset of Aipl1 patients who may benefit from gene therapy.  
 
Pre-clinical rescue studies of Aipl1 defects 
AAV-mediated gene replacement studies have successfully rescued vision in Aipl1 
hypomorphic mice (Tan et al., 2009; Sun et al., 2010) which express 20-25% of wildtype levels 
of mAIPL1. Aipl1 hypomorphic mice show slow degeneration, with photoreceptor cell loss 
beginning at 3 months of age and reduced to half of the normal outer nuclear layer (ONL) 
thickness by 8 to 10 months of age (Liu et al., 2004). In AAV-rescue studies, Aipl1 hypomorph 
degeneration was expedited with light damage (Tan et al., 2009), with the 50% reduction in ONL 
thickness accelerated to 6.25 months of age. A second strategy was used in Sun et al., 2010, 
where Aipl1 hypomorphs were crossed with Aipl1-null mice to generate F1 “Aipl1hypo” offspring, 
which exhibit a 75% reduction in ONL thickness by 11 months of age. These Aipl1 hypomorph 
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mouse models were successfully treated with single-stranded AAV2 (Tan et al., 2009) and 
AAV5 (Sun et al., 2010).  
In contrast, AAV2 and AAV5 were unable to rescue photoreceptor structure and function 
in Aipl1-null mice (Sun et al., 2010), further confirming the subpar efficiency of AAV2 and 5 in 
photoreceptor targeting. Two independent Aipl1-null models recapitulate severe LCA with early 
visual defects accompanied by rapid degeneration, although one model demonstrates 13% of 
surviving photoreceptors in the peripheral retina at P60 (Dyer et al., 2004) whereas a second 
shows complete photoreceptor loss by P24 (Ramamurthy et al., 2004). Vision rescue was 
achieved in the former Aipl1-null model with AAV8 (Tan et al., 2009; Sun et al., 2010). 
However, more recent developments in AAV may improve vision rescue effects in the Aipl1-null 
mouse, which requires rapid and robust transduction to combat the extremely rapid retinal 
degeneration beginning at P8 and complete by P24.  
 
Objective 
The combination of recent developments in AAV increase the capability to rescue rapid 
retinal degeneration associated with photoreceptor gene defects. One such photoreceptor defect 
is Aipl1, in which our Aipl1-null mouse model shows the most rapid retinal degeneration of all 
mouse models. Study 1 is proof-of-principle that advancements in AAV significantly improve 
photoreceptor transduction over first generation AAV vectors, which were sufficient for slow 
retinal degeneration. Vision rescue achieved in Aipl1-null mice using self-complementary capsid 
mutant AAV8 is compared to first generation single-stranded AAV8 through functional, 
morphological, and biochemical assays. In addition, clinical reports of Aipl1 patients with 
relatively slower forms of retinal degeneration relative to LCA indicate that a population of Aipl1 
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patients may potentially benefit from gene replacement therapy. Study 2 provides a mouse model 
of an Aipl1 patient mutation showing a cone-rod dystrophy phenotype, demonstrating that Aipl1 
mutations are potentially amenable to gene replacement therapy. Chapter 4 concludes with a 
summary of findings and the implications of gene replacement therapy for inherited retinal 
degeneration associated with Aipl1.  
21 
 
Figures 
Fig. 1 
 
Fig. 1. The neural retina and RPE. (a) The laminated neural retina is made up of three cellular 
layers: the outer nuclear layer (ONL) is rod and cone photoreceptor nuclei; inner nuclear layer 
(INL) is composed of bipolar, horizontal, and amacrine cells; and the retinal ganglion cell (RGC) 
layer of which the axons form the optic nerve. The retinal pigmented epithelium (RPE) is located 
between photoreceptor outer segments (OS) and the vascular choroid, and is essential in the 
visual retinoid cycle. (b) The visual retinoid cycle involves enzymes in both the RPE and PR for 
regeneration of 11-cis retinal that upon photoisomerization, leads to activation of opsin and 
initiation of visual signal transduction. Abbreviations: ATP-binding cassette transporter, retina-
specific (ABCR), retinol dehydrogenase (RDH), interphotoreceptor retinoid binding protein 
(IRBP), cellular retinoid binding protein (CRBP), lecithin retinol acyltransferase (LRAT), retinal 
pigment epithelium-specific protein, 65 kDa (RPE65), cellular retinaldehyde binding protein 
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(CRALBP), retinol binding protein 4 (RBP4). Adapted from (Besch et al., 2003; Kuksa et al., 
2003).  
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Fig. 2 
 
Fig. 2. Genes associated with inherited retinal degeneration (IRD). Each IRD is associated 
with defects in numerous genes, some of which are also associated with other IRDs (in 
overlapping areas). LCA, the most severe of IRDs, has over 16 associated genes, with recent 
defects in Cabp4 (2010), Iqcb1 (2011), and Kcnj13 (2011) reported. Apart from these select few 
with unknown function, most genes associated with LCA have known mechanisms of 
dysfunction mainly in phototransduction (navy font), ciliary transport (pink), and visual retinoid 
cycle (maroon). Other important classes of dysfunction are retinal development and structure 
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(dark green), photoreceptor OS structure (purple), and ion channels (light green). RP, on the 
other hand, is linked to over 50 genes, in which many have unknown functions. Genetic testing is 
not routinely conducted in CORD patients and it is predicted that many genes remain 
unidentified. Symbols: genes associated with autosomal dominant disease are *adLCA, “adRP, 
^adCORD. Adapted from (Berger et al., 2010).  
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Fig. 3 
 
Fig. 3. Production of AAV. Original AAV production involved co-transfection of a plasmid 
with the transgene of choice cloned between two 145-bp inverted terminal repeats (ITRs) and a 
mini plasmid encoding necessary AAV rep and cap genes, alongside adenovirus (Ad) infection 
into 293 cells. Subsequent purification of Ad particles from rAAV preparations was required 
with this method. Understanding of the role of Ad genes in AAV replication substituted Ad 
infection with a helper plasmid encoding Ad genes E1a, E1b, E2a, and VA. Adapted from 
(Goncalves 2005). 
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Fig. 4 
 
Fig. 4. Single-stranded and self-complementaryAAV. Replication of AAV particles initiates at 
the 3’ ITR (step 1) which acts as a primer for host DNA polymerase. Following elongation, the 
5’ ITR is duplicated (step 2), and this duplex ITR is isomerized to a double-hairpin conformation 
(step 3) to create a new primer site for re-initiation of DNA synthesis (step 4). While the 3’ ITR 
is elongated and daughter strand displaced (ssAAV genome) (step 5m, 6m), rep 78/68 binds and 
nicks at the terminal resolution site (trs) of the ITR before being reached by DNA elongation 
occurring at the other end. Following elongation at the opposite end, the resultant duplex 
monomer (top structure following step 6m) recreates the template for isomerization in step 3. 
scAAV genomes are produced through deletion of one trs site from one ITR, such that the rep 
protein no longer creates the essential nick. The replication complex copies through the hairpin, 
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producing a double-stranded inverted repeat, with a wildtype ITR at both ends and a mutated 
ITR in the middle (structure following step 6d). The dimeric inverted repeat undergoes normal 
replication initiating at any of the wildtype ITRs (steps 7d-9d), with displacement and generation 
of the scAAV genome, which is an inverted repeat with a complete ITR at both ends and a 
mutated ITR in the middle. Adapted from (Mccarty 2008). 
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Fig. 5 
 
Fig. 5. Subretinal and intravitreal routes of intraocular gene delivery. Subretinal 
administration deposits viral solution between the retinal pigmented epithelium (RPE) and 
photoreceptors, ideal for transduction of either of these cell types. However, a puncture through 
the retina is required in subretinal injections leading to local damage and temporary local retinal 
detachment. Intravitreal injections deposit viral solution in the vitreal space behind the lens and 
does not cause retinal damage or detachment. Adapted from (Colella et al., 2009). 
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Fig. 6 
 
Fig. 6. Aipl1 domains and function. Aipl1 (a) contains a FKBP-like domain, 3 tetracopeptide 
repeat (TPR) domains, and a C-terminal region present only in primate isoforms. (b) Three 
different patient mutations (orange, blue, red arrows and underline) disrupt a repeating PxxP 
motif (black underline) present in the C-terminal proline-rich hinge region (grey boxes). (c) 
Aipl1 has been sporadically associated with inherited retinal degenerations outside of LCA, two 
of such cases associated with hinge region mutation, P351Δ12.   
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Fig. 7 
 
 
Fig. 7. Spectrum of IRD associated with Aipl1. Aipl1 is associated mainly with Leber 
congenital amaurosis (LCA), a rapid rod and cone dystrophy on the most severe end of the 
spectrum of inherited retinal degenerations (IRD), with severe visual deficits and loss of ERGs 
within the first few months of life. Additionally, Aipl1 mutations were found in patients with 
cone-rod dystrophy (CORD) and juvenile early onset-retinitis pigmentosa (RP) in a few isolated 
cases. CORD and RP show later onset and slower progression, with cone- and rod-mediated 
visual deficits, respectively, presenting as the first visual symptoms.  
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Chapter 2 
 
Gene replacement therapy for Aipl1-null mice, a model of severe Leber 
congenital amaurosis 
 
Abstract 
Defects in the photoreceptor specific gene aryl hydrocarbon receptor interacting protein-
like 1 (Aipl1) are associated with Leber congenital amaurosis (LCA), a childhood blinding 
disease with early-onset retinal degeneration and vision loss. Furthermore, Aipl1 defects are 
characterized at the most severe end of the LCA spectrum. The rapid photoreceptor degeneration 
and vision loss observed in the LCA patient population is mimicked in a mouse model lacking 
AIPL1. Using this model, we evaluated if gene replacement therapy using recent advancements 
in adeno-associated viral vectors (AAV) provides advantages in preventing rapid retinal 
degeneration. Specifically, we demonstrated that the novel self-complementary Y733F capsid 
mutant AAV2/8 (sc-Y733F-AAV2/8) provided greater preservation of photoreceptors and 
functional vision in Aipl1 null mice compared to single-stranded AAV2/8. The benefits of sc-
Y733F-AAV were evident following viral administration during the active phase of retinal 
degeneration, where only sc-Y733F-AAV treatment achieved functional vision rescue. This 
result was likely due to higher and earlier onset of Aipl1 expression. Based on our studies, we 
conclude that the sc-Y733F-AAV2/8 viral vector, to date, achieves the best rescue for rapid 
retinal degeneration in Aipl1 null mice. Our results provide important considerations for viral 
vectors to be used in future gene therapy clinical trials targeting a wider severity spectrum of 
inherited retinal dystrophies. 
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Introduction 
Inherited retinal dystrophies are a large group of clinically and genetically diverse 
conditions estimated to affect 1 in 3000 people (Daiger et al., 2007; Sun et al., 2010). The 
earliest and most severe form is Leber congenital amaurosis (LCA), which is estimated to 
account for ≥ 5% of inherited retinopathies (Schappert-Kimmijser et al., 1959; Koenekoop 
2004). LCA is diagnosed with clinical findings of severely impaired visual function shortly after 
birth, sluggish pupillary responses, nystagmus, and an absent or markedly reduced 
electroretinogram (ERG). Patients with LCA may also exhibit fundus changes, photophobia, the 
occulodigital sign, keratoconus, and cataract (Schappert-Kimmijser et al., 1959; Foxman et al., 
1985). To date, LCA is associated with mutations in at least 15 different genes expressed in 
either photoreceptor or retinal pigment epithelium (RPE) cells (Human Gene Mutation Database, 
http://www.hgmd.org, April 12, 2011). Clinical heterogeneity within LCA had long been 
recognized (Noble and Carr 1978; Foxman et al., 1985; Schroeder et al., 1987; Fulton et al., 
1996), but more recent genotype-phenotype correlation studies showed subtle but important 
differences in fundus appearance, visual acuity, and disease progression (Perrault et al., 1999; 
Hanein et al., 2004; Galvin et al., 2005).  
 Greater understanding of the molecular basis of genetic defects in inherited retinopathies 
coupled with developments in viral-mediated gene delivery have led to potential therapies for 
some retinal dystrophies, which were a previously untreatable group of diseases. Defects in 
retinal pigment epithelium-specific protein 65 kDa (RPE65) are associated with autosomal 
recessive retinitis pigmentosa and LCA. In multiple animal models, mutations in RPE65 lead to 
vision loss but photoreceptor neurons develop normally and survive for an extended period 
(Wrigstad et al., 1994; Redmond et al., 1998; Pang et al., 2005). This characteristic of RPE65 
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mutations was crucial in successful preclinical trials in multiple animal models (Acland et al., 
2001; Chen et al., 2006; Pang et al., 2006; Bennicelli et al., 2008). Although patients with RPE65 
mutations exhibit greater photoreceptor degeneration than animal models, optical coherence 
tomography (OCT) demonstrated preservation of the photoreceptor cell layer that is greater than 
predicted from the level of visual dysfunction (Jacobson et al., 2005). These findings indicated 
that there is a window of time for therapeutic intervention, which made RPE65 patients an ideal 
initial target for gene therapy trials. Landmark clinical trials which delivered exogenous RPE65 
gene using the adeno-associated virus 2 (AAV2), showed visual improvements in patients 
(Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; 
Cideciyan et al., 2009; Simonelli et al., 2010), and are paving the way for gene therapy for 
inherited retinal degenerative diseases associated with other genetic defects.  
On the other end of the disease spectrum are mutations linked to LCA that cause rapid 
photoreceptor degeneration. The degeneration is pronounced when associated with defects in 
Aryl hydrocarbon receptor interacting protein-like 1 (Aipl1). AIPL1 is a 386 amino acid protein 
that belongs to the FK506 binding protein (FKBP) family of chaperone proteins (Sohocki et al., 
2000a), and is expressed early and specifically in photoreceptors (Hendrickson et al., 2008). 
AIPL1 is crucial for the stability of rod phosphodiesterase 6 (PDE6), an enzyme that is involved 
in cyclic GMP phototransduction signaling (Liu et al., 2004; Ramamurthy et al., 2004; 
Kolandaivelu et al., 2009). Although the role in cone photoreceptors is not fully understood, 
AIPL1 is required for cone function and survival (Kirschman et al., 2010). In the Aipl1 null 
mouse, both rod and cone electroretinogram (ERG) responses are absent and complete 
photoreceptor cell loss occurs by 3 weeks of age (Ramamurthy et al., 2004). Patients with Aipl1 
mutations, implicated in 5-7% of LCA cases and several incidences of juvenile retinitis 
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pigmentosa and cone-rod dystrophy (Sohocki et al., 2000b), have a stable but drastically reduced 
visual acuity by the first decade in life, ranging from 20/200 to no light perception (Galvin et al., 
2005; Simonelli et al., 2007; Walia et al., 2010). The level of photoreceptor survival in patients 
has not been extensively examined, but two recent studies found photoreceptors in OCT scans of 
patients with mutations in Aipl1 (Jacobson et al., 2011; Testa et al., 2011). While the window of 
therapeutic opportunity is smaller in Aipl1 defects due to rapid photoreceptor degeneration, these 
findings highlight the possibility that patients with Aipl1 defects could benefit from early gene 
replacement therapy.  
Two important proof-of-concept studies used adeno-associated viral (AAV)-mediated 
gene replacement therapy in the Aipl1 hypomorphic and null mouse (Tan et al., 2009; Sun et al., 
2010). These were the first studies to show that Aipl1 replacement could restore functional rod 
and cone PDE6 and prevent the loss of photoreceptors. Since these two studies, advancements in 
virology resulted in AAV vectors with increased transduction efficiency and shortened onset of 
expression. The first development was self-complementary AAV, which produces a double 
stranded gene vector that is more stable and eliminates the need for second-strand DNA 
synthesis (Mccarty et al., 2001). These characteristics conferred both earlier onset and increased 
transduction efficiency compared to single-stranded AAV (Natkunarajah et al., 2008; Petersen-
Jones et al., 2009; Kong et al., 2010). The second development was mutations of surface-
exposed tyrosine residues on the viral capsid. The resultant decrease in capsid tyrosine 
phosphorylation reduces ubiquitination of viral particles and subsequently improves nuclear 
transport and transduction efficiency (Zhong et al., 2007; Zhong et al., 2008b).  
The aim of this study was to utilize these developments in AAV vectors in order to 
maximize therapeutic effects of gene replacement therapy for rapid retinal degeneration. 
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Specifically, we assessed the efficiency of gene replacement therapy using single-stranded 
AAV2/8 (ssAAV) or the novel self-complementary Y733F tyrosine capsid mutant AAV2/8 
(scAAV) delivering the human Aipl1 gene. In these studies, we first assessed the onset and 
efficiency of gene expression achieved with each virus in wild-type retina. We further evaluated 
the level of vision rescue that ssAAV or scAAV provides to Aipl1-/- mouse, a model of rapid 
retinal degeneration, following treatment at an early and later stage of photoreceptor 
degeneration.  
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Materials and Methods 
Animals 
Aipl1 knockout mice were generated and characterized previously (Ramamurthy et al., 2004). 
Aipl1 knockout mice and wild-type used in this study are in a mixed C57Bl/129sv background. 
Mice were maintained under 12-h light / 12-h dark light cycles. All experiments involving 
animals were approved by the Institutional Animal Care and Use Committee at West Virginia 
University.  
Generation of recombinant AAV vectors 
Full-length human Aipl1 was amplified from human retinal cDNA using Aipl1 specific primers 
and cloned into the multiple cloning site of the parental pAAV-RKp-zsGreen vector to generate 
the pAAV-RKp-hAipl1 plasmid, which was used to produce the ssAAV2/8-RKp-hAipl1 viral 
vector as described in Sun et al (Sun et al., 2010). RKp-hAipl1 was amplified from pAAV-RKp-
hAipl1 with primers that engineered flanking Kpn-I and Eag-I sites, and cloned into the self-
complementary AAV packaging vector, to generate the SC-RKp-hAipl1 plasmid. This plasmid 
was used to produce the scAAV2/8-Y733F-RKp-hAipl1 viral vector. The self-complementary-
Y733F-AAV2/8 pseudotyped viral vector was generated as described previously, using the 
AAV8 capsid protein with Y733F surface-exposed tyrosine residue mutation (Zolotukhin et al., 
2002; Zhong et al., 2008b). All polymerase chain reaction (PCR) amplifications were performed 
with Phusion GC DNA polymerase master mix (Finnymes, Thermo Scientific, Lafayette, CO, 
USA), following manufacturer instructions for cycling conditions. All plasmids were sequenced 
with the Big Dye Terminator ready reaction kit (Perkin Elmer, Waltham, MA, USA).  
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Subretinal injection 
Aipl1-/- mice injected at postnatal day 2 (P2) were anesthetized by chilling on ice. P10 Aipl1-/- 
mice and P14 wild-type mice were placed under general anesthesia with an intraperitoneal 
injection of ketamine (90 mg kg-1) / xylazine (9 mg kg-1) and received a drop of dilation solution, 
consisting of a 1:1 mixture of tropicamide (1%, Alcon, Fort Worth, TX, USA) : phenylephrine 
hydrochloride (2.5%, Bausch and Lomb, Tampa, FL, USA).  For injection into mice prior to 
eyelid opening, an incision was made along the natural future eyelid line with surgical vannas 
scissors. A small incision was then made in the sclera just outside the pupillary margin with a 36-
gauge needle. Viral solution was injected into the subretinal space using a pulled glass pipette 
attached to a pneumatic injector (MINJ-PD, Tritech Research, Los Angeles, CA, USA) using a 
transcorneal approach (Matsuda and Cepko 2004). Self-complementary and single-stranded 
AAV solutions were titer matched to 1.2x1013 viral particles per ml by diluting with phosphate 
buffered saline (PBS). Each animal received 1.0 µl of AAV in the right eye, and no injection in 
the untreated contralateral eye. Visualization during injection was aided by the addition of 0.1% 
fluorescein (100 mg ml-1 AK-FLUOR, Alcon, Fort Worth, TX, USA) to the viral solutions.  
Electroretinographic (ERG) analysis 
Mice were dark-adapted overnight prior to testing. Eyes were topically dilated with a 1:1 mixture 
of tropicamide: phenylephrine hydrochloride. For ERG testing, mice were placed on a heated 
platform with continuous flow of isoflurane anesthesia through a nose cone (1.5% isoflurane 
with 2.5 liters per min (lpm) oxygen flow rate). A reference electrode was placed subcutaneously 
in the scalp. ERG responses were recorded from both eyes with silver wire electrodes placed on 
each cornea, with contact being made with a drop of hypromellose solution (2% hypromellose in 
PBS) (Gonioscopic Prism Solution, Wilson Ophthalmic, Mustang, OK, USA). Rod dominated 
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responses were elicited in the dark with flashes of LED white light at increasing flash intensities. 
Light-adapted cone responses were elicited in the presence of a 41 cd/m2 rod-desensitizing white 
background light with 2.5 cd · s/m2 LED white light flashes. ERGs were performed on the UTAS 
Visual Diagnostic System with BigShot Ganzfeld with UBA-4200 amplifier and interface, and 
EMWIN 9.0.0 software (LKC Technologies, Gaithersburg, MD, USA).   
Vision-dependent behavioral assay 
Morris water maze assay to test for visual dependent behavior was performed as described in 
Pang et al (Pang et al., 2008). Mice were tested in a dim-lit room at 1.5 to 2.0 lux. Briefly, the 
task involved swimming in a 4 foot diameter water pool to an escape platform marked with a 
flag as a visual guidance cue. The time to reach the escape platform was recorded. The escape 
platform was washed between each trial to eliminate non-vision guided cues. Mice were trained 
to this task for 3 days, consisting of 5 trials each day. During this training period, the escape 
platform was stationary and the drop-off location of the mouse differed for each trial. On the 4th 
training day, the escape platform was moved to a different location in each trial. On the test day, 
day 5, the escape platform was also moved to a different location in each trial. However, to 
control for differences in swimming distances, the platform locations were kept constant for 
every mouse tested across all treatment groups. The reported times were taken from this final test 
day as group average times.  
Immunoblotting, immunohistology, and morphometric analysis 
Mice were euthanized by CO2 inhalation and eyes were enucleated. For immunoblots, flash 
frozen retinal samples dissected from enucleated eyes were sonicated in 6 M urea buffer (6 M 
urea, 4% sodium dodecyl sulfate (SDS), 0.5 M Tris pH 6.8, 10 mg/ml DTT). Protein 
concentrations were estimated using a NanoDrop spectrophotometer (Thermo Scientific). 100 µg 
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total protein samples were resolved on 10% resolving SDS-polyacrylamide gel, and transferred 
onto polyvinylidene difluoride membranes (Immunobilon-FL, Millipore, Billerica, MA, USA). 
Membranes were blocked with blocking buffer (Rockland Inc., Gilbertsville, PA, USA) for 30 
min at room temperature, and incubated with the indicated primary antibodies. Blots were 
washed in PBST (Phosphate buffered saline, 137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4·7H2O, 1.4 mM KH2PO4, with 0.1% Tween-20) twice for 20 min and incubated in 
secondary antibody, goat anti-rabbit IRDye 680 (LI-COR Biosciences, Lincoln, NE, USA) for 30 
min at room temperature. After 3 washes with PBST, membranes were scanned using the 
Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA), and bands 
quantified using Odyssey Infrared Imaging System software.  
For immunohistochemical studies, eyes were immersed in 4% paraformaldehyde fixative 
for 15 min prior to removal of the anterior segments and lens. Eyecups were fixed for an 
additional 4 h, washed in PBS (Phosphate buffered saline) for 20 min, incubated in 10% 
sucrose/PBS for 1 h at room temperature, and transferred to 20% sucrose/PBS for overnight 
incubation at 4°C. Eyes were then incubated in 1:1 mixture of 20% sucrose in PBS:OCT (Cryo 
Optimal Cutting Temperature Compound, Sakura, Torrance, CA, USA) for 1 h, and flash frozen 
in OCT. Cryosectioning was performed with a Leica CM1850 Cryostat, and serial retinal 
sections of 14 µm thickness were mounted on Superfrost Plus slides (Fisher Scientific, 
Pittsburgh, PA, USA). Retinal sections mounted on slides were washed with 1X PBSTx (1X 
PBS with 0.1% TritonX-100), and incubated for 1 hr in blocking buffer (1X PBS with 5% goat 
sera, 0.5% TritonX-100, 0.05% sodium azide). Retinal sections were incubated with primary 
antibody for 2-3 hrs, followed by three 10 min washes with 1X PBSTx before incubation with 
secondary antibody (Alexa Fluor-488 or Alexa-Fluor 568, Invitrogen, Carlesbad, CA, USA) for 
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30 min. The nuclear marker, 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen, 1:5000 dilution) 
was added for 10 min, and washed with 1X PBSTx before mounting with Prolong anti-fade 
reagent (Invitrogen) and coverslipping. Slides were viewed and imaged on a laser scanning 
confocal (Zeiss LSM 510) on a Zeiss LSM AxioImager Z1 microscope. Outer nuclear layer cell 
quantification was conducted on retinal sections from 3 different animals with the highest ERG 
responses in each treatment group. Serial sections for each retina were examined to determine 
the area with greatest photoreceptor preservation, which typically showed a uniform preservation 
in 40-50% of serial sections. Confocal images of DAPI stained nuclei were taken at five fixed 
locations of a section, to control for variability across the eyecup. Confocal images were 
analyzed using ImageJ software (NIH, Bethesda, MD) to determine the photoreceptor cell count, 
which was reported as an average of the 15 measurements. Each measurement spanned 
approximately 200 µm in width of the retina. 
For retinal wholemounts, eyes were enucleated with the orientation maintained by 
puncturing at the dorsal position, and fixed in 4% paraformaldehyde for 15 min. The anterior 
segments were removed to create an eyecup, and a vertical incision was created at the most 
dorsal position. The retina was carefully removed from the eyecup and fixed for an additional 6-
12 hrs at 4°C. The retina was washed twice for 30 min prior to incubation in primary antibody 
for 12-24 hrs at 4°C. Removal of excess primary antibody was conducted with two 30 min 
washes, followed by incubation in secondary antibody for 12-24 hrs at 4°C, washed twice for 20 
min, and mounted and coverslipped. Wholemounts were viewed and imaged on an Olympus 
AX70 Provis microscope with an Optronics Microfire color CCD camera (Optronics, Golenta, 
CA, USA), using Stereo Investigator (MBF Bioscience, Milliston, VT, USA) and PictureFrame 
(Optronics, Golenta, CA, USA) software. Quantification of wholemounts was conducted using 
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ImageJ software to analyze 20x objective wholemount images taken with the same exposure 
time. Each data point, expressed in fluorescent arbitrary units, was an average of 9 measurements 
obtained from 3 injected retinas with 3 images for each retina. 
The following primary antibodies were used at the indicated dilutions: Human AIPL1 
(1:1000) (Ramamurthy et al., 2004), PDE6αβγ (MOE) (1:2000) (CytoSignal Inc., Irvine, CA, 
USA), PDE6β (1:1000) (Affinity BioReagents, Golden, CO, USA), cone PDEα’ (1:1000) 
(Kirschman et al., 2010), rod opsin (4D2) (1:2000) (gift from Dr. Robert Molday, University of 
British Columbia, Vancouver, British Columbia, Canada), red/green opsin (1:1000) (Chemicon, 
Millipore, Billerica, MA, USA), PKCα (1:2000) (Thermo Fisher Scientific, Inc., Pittsburgh, PA, 
USA). Rhodamine peanut agglutinin (PNA) (1:500) (Vector Laboratories, Inc., Burlingame, CA, 
USA) and DAPI (1:5000) (4’,6-diamidino-2-phenylindole, Invitrogen) were also used in 
immunocytochemistry. 
Histologic, semithin sections, and transmission electron microscopy 
For hematoxylin and eosin stained images, enucleated whole eyes were fixed in Alcoholic Z-fix 
(Excalibur Pathology) for 48 hrs at room temperature. Serial sections of paraffin embedded fixed 
whole eyes were mounted on slides (Excalibur Pathology). Images were collected on an 
Olympus AX70 Provis microscope using PictureFrame software (Optronics, Golenta, CA, USA).  
For light and transmission electron microscopy, enucleated eyes were lightly fixed in 
freshly prepared fixative (2% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M cacodylate buffer, 
pH 7.5) for 30 min. The anterior segment and lens were removed and eye cups were returned to 
fixative for 48 hours at room temperature, prior to dissection into 6-8 wedge-shaped pieces. 
Wedges were dehydrated in a graded ethanol series, then embedded in Polybed 812 
(PolySciences, Inc.,Warrington, PA, USA). Semi-thin (1 μm) sections were collected onto glass 
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slides, stained with toluidine blue, and visualized using a Zeiss Axioimager 2 microscope 
equipped with EC Plan-Neofluar 40x (N.A. 0.75) and 100x (1.3 N.A.) objectives to identify best 
rescued areas. Thin sections (ca. 80 nm) from selected wedges were collected onto nickel grids, 
stained with 2% uranyl acetate and lead citrate, and imaged using an FEI Morgagni transmission 
electron microscope at 80 kV. 
Statistical analyses 
Statistical analyses were conducted on GraphPad Prism4 software (GraphPad Software, Inc., La 
Jolla, CA, USA), using one-tailed unpaired t-tests for two group comparisons, and ANOVA 
followed by Tukey-Kramer HSD post-hoc tests for multiple group comparisons.  
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Results 
Self-complementary AAV capsid mutant induces earlier and higher expression of hAIPL1 
in retina 
Self-complementary Y733F tyrosine capsid mutant AAV2/8 combines two recent 
developments in AAV vectors shown to increase transduction efficiency and decrease expression 
latency of reporter genes (Natkunarajah et al., 2008; Petersen-Jones et al., 2009; Kong et al., 
2010). To compare the onset and levels of expression of single-stranded AAV and self-
complementary capsid mutant AAV, we injected ssAAV-RKp-hAipl1 (henceforth referred to as 
ssAAV) or scAAV-Y733F-RKp-hAipl1 (henceforth referred to as scAAV) into postnatal day 14 
(P14) wild-type retina. Viral titers were matched between ssAAV and scAAV for all experiments 
throughout this study. The vectors expressed the human Aipl1 gene under the short rhodopsin 
kinase promoter (RKp), which is active in both rod and cone photoreceptor cells as early as P2 
(Young et al., 2003; Young et al., 2005; Khani et al., 2007). Expression of exogenously delivered 
human AIPL1 was investigated through immunofluorescent staining of whole mounted injected 
eyes with an antibody that specifically recognizes the human isoform of AIPL1. Eyes injected 
with ssAAV exhibited low AIPL1 expression in sparse areas beginning at post-injection (pi) day 
3, with progressive increases at pi day 5 and 7. Expression of AIPL1 began to plateau between pi 
day 7 and 14 (Fig. 1A). In comparison, eyes injected with scAAV exhibited expression of AIPL1 
in larger areas beginning at pi day 2 and uniformly high expression at pi day 3. Expression of 
AIPL1 increased steadily and uniformly at pi day 5, 7, and 14 (Fig. 1A). Fluorescent counts 
quantifying AIPL1 expression were conducted on three treated retina per post-injection time 
point. Mean fluorescent counts were significantly higher in scAAV treated eyes than ssAAV 
treated eyes at pi day 3, 5, and 14 (p < 0.0005) (Fig. 1B). scAAV treated retina had a four-fold 
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higher mean fluorescent count than ssAAV at pi day 3, and a two-fold difference at pi day 5 and 
pi day 14. Differences in AIPL1 expression were particularly evident at earlier time points, with 
expression levels of scAAV at pi 3 greater than levels of ssAAV at pi 5. 
 
Early administration of AAV-mediated gene replacement therapy efficiently rescues 
photoreceptor function in Aipl1-/- mice  
Aipl1-/- mice exhibit rapid and severe photoreceptor degeneration (Dyer et al., 2004; 
Ramamurthy et al., 2004), with initiation of cell death at postnatal day 8 (P8) (Supplementary 
Fig. 1). In addition, photoreceptor cells in these mice are not functional at any age tested 
(Ramamurthy et al., 2004). Our goal was to compare the efficacy of ssAAV and scAAV in 
preventing cell death and in rescuing visual function. Therefore, we injected AAV-hAipl1 
subretinally into one eye of Aipl1-/- mice at postnatal day 2 (P2). At this early stage of retinal 
development, rod photoreceptors in mice are beginning to form. Electroretinograms (ERGs), a 
measure of light dependent electrical responses from photoreceptor cells and downstream 
neurons, were conducted to evaluate photoreceptor function after treatment with either ssAAV or 
scAAV. The a-wave in ERG correlates with photoreceptor activity, while the b-wave arises 
mainly due to downstream bipolar cell activity. Representative ERG recordings at P30 under 
dark-adapted (Fig. 2A) and light-adapted conditions (Fig. 2B), showed restoration of scotopic 
and photopic ERG responses in ssAAV and scAAV treated eyes compared to a complete absence 
of response in the contralateral untreated eye. The scAAV treated eye showed greater a- and b-
wave amplitudes and oscillatory potentials than the ssAAV treated eye at all dark-adapted 
scotopic flash intensities of -3.6, -1.6, -0.6, and 0.4 log (cd · s/m2) flashes. At a flash intensity of 
-0.6 log (cd · s/m2), the photoreceptor responses (a-wave amplitudes) of individual mice in each 
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treatment group showed intergroup variability (Fig. 2C). However, the mean group average for 
scAAV was statistically higher than for ssAAV treated mice (p = 0.027; ssAAV treated mean = 
49.5 ± 8.7 µV, n = 10; scAAV treated mean = 79.5 ± 11.6 µV, n = 10). This difference in group 
means of a-wave amplitudes was statistically significant at every scotopic flash intensity 
recorded (p values indicated in figure, ranging from p = 0.017 to p = 0.027) (Fig. 2D).  
 
Early administration of AAV-mediated gene replacement therapy restores rod and cone 
PDE6 expression and slows photoreceptor degeneration in Aipl1-/- mice 
To evaluate the effects of Aipl1 replacement on photoreceptor survival, we examined the 
retinal morphology in AAV treated and untreated control eyes. Immunocytochemical and 
morphometric analyses were conducted at P65 after a single injection at P2. As expected, treated 
eyes showed expression of hAIPL1 in photoreceptor inner segments and outer plexiform layer 
(Kirschman et al., 2010; Sun et al., 2010) (Fig. 3A). Concomitant with the expression of hAIPL1, 
rod and cone PDE6 was observed along with rod and cone opsins, indicating the presence of 
intact rod and cone outer segments (Fig 3A). ssAAV treated eyes showed 4-5 rows of 
photoreceptor cell nuclei compared to a complete loss of photoreceptors in the contralateral 
untreated eye. scAAV treated retina had 5-6 rows of photoreceptor nuclei (Fig. 3A, and 
Supplementary Fig. 2). To quantify the observed differences in outer nuclear layer thickness, 
photoreceptor cell nuclei counts were conducted on retina from each treatment group. The mean 
number of photoreceptor cell nuclei of scAAV treated retina was significantly greater than 
ssAAV treated retina by 45% (p = 0.005; ssAAV mean = 125.92 ± 14.43; scAAV mean = 182.85 
± 13.42) (Fig. 3B). In agreement with our ERG and morphology results, western blots showed 
that retina from scAAV treated animals expressed higher levels of AIPL1 and rod PDE6 than 
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ssAAV treated animals (Fig. 3C). This trend was also observed when protein levels were 
examined at P35, where all scAAV treated animals expressed higher levels of AIPL1 and rod 
PDE6 (Supplementary Fig. 3) at this earlier post-injection time point. 
 
Early administration of AAV-mediated gene replacement therapy preserves photoreceptor 
ultrastructure 
The effectiveness of AAV-mediated gene replacement therapy on preserving 
photoreceptor ultrastructure was evaluated through light and transmission electron microscopy. 
Semi-thin sections showed scAAV treated retina with longer inner and outer segments compared 
to ssAAV treated retina (Fig. 4A). At best, outer segments in ssAAV treated retina were 40-50% 
of the length of outer segments in an age-matched wild-type retina, whereas scAAV treated 
retina were 50-60% of wild-type retina (Fig 4A). Additionally, semi-thin sections showed similar 
findings to immunohistochemical studies in outer nuclear layer thickness, with ssAAV treated 
retina with 4-5 rows of nuclei and scAAV treated retina with 5-6 rows (Fig. 4A). 
Ultrastructurally, both ssAAV and scAAV treated retina displayed intact photoreceptor outer 
segments with normally organized and densely stacked disc membranes, similar to wild-type 
retina (Fig. 4B).  
 
Early administration of AAV-mediated gene replacement therapy restores visually guided 
behavior in Aipl1-/- mice 
To assess whether the observed rescue of electrophysiological responses and retinal 
morphology result in improvements in visually guided behavior, P2 AAV treated mice were 
tested with the Morris water maze at P60. The Morris water maze, adapted from Pang et al. 
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(Pang et al., 2008), tested for the ability of the mice to visually locate an escape platform. Under 
dim light conditions, untreated wild-type Aipl1+/+ mice took 3.45 ± 0.44 sec (n = 7) to locate 
the platform (Fig. 5). In comparison, untreated Aipl1-/- mice located the platform in 24.09 ± 2.72 
sec (n = 8), which was significantly greater than wild-type mice (p < 0.001). Aipl1-/- mice 
treated with ssAAV found the platform in 6.88 ± 0.87 sec (n = 6), and scAAV treated mice took 
7.82 ± 0.81 sec (n = 7), both of which were significantly less than untreated Aipl1-/- mice (p < 
0.001). There was no statistical difference between ssAAV treated and wild-type mice, between 
scAAV treated and wild-type mice, or between ssAAV and scAAV treated mice (p > 0.05 for all 
comparisons, Analysis of Variance (ANOVA) with Tukey-Kramer Honestly Significant 
Difference (HSD) statistical analysis).  
 
Gene replacement therapy with self-complementary AAV capsid mutant effectively rescues 
rod and cone function in Aipl1-/- mice with active photoreceptor degeneration 
Our experiments comparing transduction kinetics of ssAAV and scAAV in wild-type 
retina demonstrated higher expression of AIPL1 at earlier time points with scAAV treatment. We 
hypothesized that this characteristic of scAAV is important in maximizing rescue of 
photoreceptors during active degeneration in Aipl1-/- mice, since these mice have a rapid rate of 
degeneration. To determine the efficiency of ssAAV and scAAV treatment in actively 
degenerating retina, viral injections were administered at postnatal day 10 (P10). At this stage of 
retinal development, photoreceptor cell death is evident in Aipl1-/- mice (Supplementary Fig. 1). 
ERG recordings were conducted at P30 to examine the effects of the delayed ssAAV and scAAV 
treatment on photoreceptor function. Representative ERG traces showed robust scotopic and 
photopic responses elicited from scAAV treated animals compared to weak responses from 
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ssAAV treated animals (Fig. 6A, B). The photoreceptor response (a-wave amplitudes) of 
individual mice in each treatment group showed all scAAV treated animals with higher a-wave 
amplitudes than ssAAV treated animals, and a significant difference in group means (p = 0.0006; 
ssAAV treated mean = 4.22 ± 2.17 µV, n = 9; scAAV treated mean = 47.67 ± 10.73 µV, n = 9) 
(Fig. 6C), under dark-adapted conditions with a flash intensity of -0.6 log (cd · s/m2). 
Additionally, the difference in group means between ssAAV and scAAV treatment was 
significant for a-wave and b-wave amplitudes recorded under dark-adapted conditions, at all 
flash intensities of -3.6, -1.6, -0.6, and 0.4 log (cd · s/m2) (p values indicated in figure, ranging 
from p = 0.003 to p = 0.00001) (Fig 6D, E). A similar trend was observed with light-adapted 
ERG responses, a reflection of cone photoreceptor activity. A statistically significant difference 
in average b-wave amplitudes elicited under light-adapted conditions with a 0.4 log (cd · s/m2) 
flash intensity was observed (p = 0.014; ssAAV treated mean = 1.22 ± 1.22 µV, n = 9; scAAV 
treated mean = 20.44 ± 7.86 µV, n = 9) (Fig. 6F), with robust cone responses in scAAV treated 
animals. While ERG responses of ssAAV treated eyes were significantly lower than scAAV 
treated eyes, they were significantly higher than contralateral untreated eyes at all flash 
intensities (p < 0.05) (data not shown).  
 
Gene replacement therapy with self-complementary AAV capsid mutant slows rod and 
cone degeneration in Aipl1-/- mice with active photoreceptor degeneration 
In P10 treated mice, the significant difference in ERG responses between ssAAV and 
scAAV already observed at P30 led us to conduct behavioral assays and morphological analyses 
at P35. Additionally, we wanted to accurately examine the behavioral and morphological 
correlates of the low ERG responses elicited from ssAAV treated mice at P30. Morphological 
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analyses were conducted to assess preservation of photoreceptors following delayed AAV-
mediated gene replacement in Aipl1-/- mice at P10. Retina from scAAV treated animals 
maintained 5-6 rows of photoreceptor cell nuclei (Fig. 7A, and Supplementary Fig. 2). In 
comparison, retina from ssAAV treated animals showed 2-3 rows of photoreceptor cell nuclei. 
These findings were supported by our cell counting results demonstrating the presence of 
significantly greater numbers of photoreceptor cell nuclei in retina from scAAV than ssAAV 
treated animals (p = 0.0000001; ssAAV mean = 76.90 ± 11.99; scAAV mean = 275.50 ± 21.71) 
(Fig. 7B). 
Immunostaining for photoreceptor outer segment proteins such as rod and cone opsins 
revealed sparse and short outer segments in retina from ssAAV treated animals, a pattern also 
observed with immunostaining for rod and cone PDE6 (Fig. 7A). In contrast, retina from animals 
treated with scAAV displayed denser and longer rod and cone outer segments (Fig. 7A). 
Coincident with the presence of photoreceptor outer segments, retina from animals treated with 
scAAV exhibited strong expression of AIPL1 in inner segments, and rod and cone PDE6 in 
respective photoreceptor outer segments (Fig. 7A). Our immunofluorescence results are 
supported by immunoblotting experiments demonstrating higher levels of hAIPL1 and rod PDE6 
in the majority of retina from scAAV treated animals (lanes 6-10) compared to ssAAV treated 
animals (lanes 1-5) (Fig. 7C). The amount of rod PDE6 in scAAV treated retina varied from 10-
40% of wild-type levels. In comparison, the amount of rod PDE6 in ssAAV treated retinas was 
negligible, with 9% of wild-type rod PDE6 levels at best (lane 5).  
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Gene replacement therapy with self-complementary AAV capsid mutant rescues visually 
guided behavior in Aipl1-/- mice with active photoreceptor degeneration 
To evaluate visually guided behavior following treatment at postnatal day 10 (P10), mice 
were tested with the Morris water maze at P35 (Fig. 8). Similar to our previous results, Aipl1+/+ 
wild-type mice took 4.38 ± 0.45 sec (n = 6) to locate the escape platform, whereas Aipl1-/- mice 
needed 25.20 ± 6.52 sec (n = 5) (p < 0.01). ssAAV treated mice took 24.00 ± 3.51 sec (n = 8), 
which was significantly different from wild-type (p < 0.01), but not from Aipl1-/- mice (p > 
0.05). These results indicate that the visually guided behavior in P10 ssAAV treated mice was 
not improved from untreated Aipl1-/- mice. In contrast, the average time of scAAV treated mice 
to find the platform was 6.69 ± 1.30 sec (n = 7), which was significantly less than ssAAV treated 
mice and Aipl1-/- mice (p < 0.01), but  not significantly different from Aipl1+/+ mice (p > 0.05), 
indicating that treatment with scAAV at P10 restored visually dependent behavior to wild-type 
levels. Similar results were observed when a comparison was conducted between ssAAV treated 
mice demonstrating ERG responses and scAAV treated mice, where the average time of ssAAV 
treated mice (n = 4, 17.87 ± 1.82 sec) was significantly different than scAAV treated mice (n = 7, 
6.69 ± 1.30 sec) (p < 0.01), but not significantly different from Aipl1-/- mice (n = 5, 25.20 ±6.52 
sec) (p > 0.05) (ANOVA with Tukey-Kramer HSD statistical analysis). 
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Discussion 
In this study, we demonstrated that the faster and greater transduction efficiency of sc-
Y733F-AAV2/8 over ssAAV2/8 led to greater preservation of visual function in AAV-mediated 
gene replacement therapy of Aipl1 deficient mice, a model of severe Leber congenital amaurosis. 
This is the first reported study to use sc-Y733F-AAV2/8 for rescue of vision in a model of rapid 
retinal degeneration. Self-complementary AAV, shown to decrease expression latency and 
increase transduction efficiency, is generally thought to have limited use due to the halved gene 
packaging capacity of single-stranded AAV. However, it has been shown that efficient 
packaging and expression of genes up to 3.3 kb may be possible (Wu, J. et al., 2007), extending 
the utility of self complementary AAV. Additionally, the advent of capsid tyrosine mutations 
provides a simple way to increase viral efficiency without placing additional size restrictions. 
While mutations of surface-exposed tyrosine residues on viral capsids decrease ubiquitination 
which largely improves transduction efficiency, the effect on expression latency remains unclear.  
Interestingly, we observed differences between ssAAV and sc-Y733F-AAV (scAAV) 
treatments in Aipl1-/- mice treated at P2, when photoreceptors are not yet fully developed and no 
sign of degeneration is present. The aim of treating early was to provide maximal rescue of 
photoreceptors. Despite early treatment, we observed consistently lower ERG responses and 
photoreceptor cell survival in ssAAV treated compared to scAAV treated Aipl1-/- retina. 
However, the magnitude of differences between the two treatment groups did not translate into a 
difference in visually guided behavior under our lighting conditions. The observed differences 
between the two treatment groups were likely due to the lower levels of AIPL1 expression 
achieved with ssAAV, as demonstrated by our studies in wild-type retina. In contrast, the higher 
AIPL1 expression with scAAV treatment provided greater ERG responses and photoreceptor 
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survival. In addition to these benefits in preservation of photoreceptor structure and function, 
viral vectors that achieve higher expression have a practical advantage, allowing for 
administration of lower viral titers which is especially important in reducing potential adverse 
effects. The use of the scAAV viral vector, therefore, may be warranted and beneficial in gene 
replacement therapy clinical trials.  
The functional advantage of scAAV was most striking following P10 administration, 
when the Aipl1 deficient photoreceptors are undergoing active degeneration. Late treatment with 
ssAAV achieved minimal photoreceptor cell survival and low ERG responses in a fraction of the 
treated animals, with no evidence of vision guided behavior. In contrast, scAAV treated animals 
showed greater photoreceptor cell survival, with concomitant ERG responses and vision guided 
behavior. Following late scAAV treatment, ERG responses persisted until the last time point 
tested at P60 (Supplementary Fig. 4). The preservation of vision achieved with both early and 
late administration of scAAV treatment demonstrates stability of vision rescue. To summarize, in 
a clinically relevant scenario of active photoreceptor degeneration, scAAV treatment showed 
clear benefits over ssAAV in vision rescue.  
The advantages in vision rescue with scAAV treatment were likely a result of the early 
robust expression of hAIPL1 observed in our comparisons of transduction efficiency in wild-type 
retina. It took an additional 3-4 days for expression levels of AIPL1 from ssAAV treatment to 
reach a level attained by that of scAAV treatment. We speculate that the faster expression of 
AIPL1 with scAAV translates into quicker restoration of functional PDE6 and stabilization of 
cGMP levels, and subsequently greater preservation of outer segments. This proved particularly 
critical in vision rescue in mice where photoreceptor degeneration has initiated. Additionally, the 
higher expression achieved with scAAV contributed to the improved vision rescue. It is known 
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that Aipl1 hypomorphic mice, which express 20-30% of wild-type AIPL1 levels, show abnormal 
photoreceptor function and slow degeneration (Liu et al., 2004). In contrast, Aipl1 heterozygous 
mice, with 50% of protein, show no signs of photoreceptor degeneration or dysfunction 
(Ramamurthy et al., 2004). This indicates that a certain threshold level of AIPL1 is necessary for 
normal photoreceptor function and survival. The lower expression of AIPL1 achieved with 
ssAAV treatment in Aipl1-/- mice may lead to a number of photoreceptors that do not cross this 
threshold, resulting in lower photoreceptor survival and subsequent lower ERG responses. 
Higher AIPL1 expression levels achieved with scAAV treatment leads to a greater probability 
that this threshold is surpassed in a larger number of photoreceptors, hence achieving greater 
photoreceptor survival and restoration of vision.  
The demonstrated functional advantages of second generation AAV vectors, such as sc-
Y733F-AAV2/8, are important in the future progress of AAV-mediated gene replacement 
therapy clinical trials. There is an impetus to broaden gene therapy clinical trials to treat a wider 
severity spectrum of inherited retinal dystrophies. Recent clinical studies report cases of 
adolescent and adult patients with genetic defects associated with rapid retinal degeneration, who 
show varying extents of ONL preservation and inner and outer segment integrity as observed 
with optical coherence tomography (OCT). This has been observed in patients with defects in 
CEP290 (Cideciyan et al., 2007; Pasadhika et al., 2010), GUCY2D (Pasadhika et al., 2010), 
RPGRIP1 (Jacobson et al., 2007), and AIPL1 (Jacobson et al., 2011; Testa et al., 2011). These 
studies show that patients with genetic defects associated with rapid retinal degeneration may 
potentially benefit from AAV-mediated gene replacement therapy. The improved transduction 
onset and efficiency of second generation AAV vectors, such as sc-Y733F-AAV2/8, provides a 
larger therapeutic range for treating a spectrum of genetic defects with varying rates of disease 
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progression. Additionally, the longevity of such residual photoreceptors cannot be predicted for 
each patient, and the best practical option is to provide the most rapid acting and efficient 
treatment possible. It remains to be examined whether infants and young children afflicted with 
LCA have a substantial amount of photoreceptors that can be salvaged with early gene therapy 
treatment. The aim of gene therapy here would be prevention of massive loss of retinal neurons. 
Our results demonstrated that sc-Y733F-AAV2/8 also provided functional benefits over 
ssAAV2/8 in early treatment of rapid retinal degeneration. Additional concurrent progress in 
viral-mediated gene delivery and clinical characterization is necessary to advance into clinical 
trials, but emerging evidence in both areas show promising prospects for gene replacement 
therapy to successfully treat a wider spectrum of genetic defects and severities of retinal 
dystrophies.   
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Figures 
 
Fig. 1 
 
 
Fig. 1. scAAV provides earlier onset and higher expression compared to ssAAV following 
subretinal injection into wild-type retina. (A) Wholemount images from injected retina at 
indicated post-injection (pi) times. All images were taken with the same exposure time at x20 
magnification. Scale bar, 100 µm. (B) Quantitative analysis of AIPL1 expression in wholemount 
images, expressed in arbitrary units of fluorescence (AU). Except for pi 7, statistically significant 
differences in units of fluorescence between ssAAV and scAAV were observed. Error bars, 
±SEM. 
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Fig. 2 
 
 
Fig. 2. Light-dependent photoreceptor responses from Aipl1-/- mice following early AAV 
treatment. One eye of Aipl1-/- mice was injected at P02 with the indicated AAV and ERGs 
were recorded at P30. ERG responses from (A) dark- and (B) light-adapted conditions were 
measured at the indicated log (cd · s/m2) flash intensities. Traces from a contralateral untreated 
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eye and an age-matched wild-type mouse are shown for comparison. (C) Dark-adapted 
photoresponses from Aipl1-/- treated mice at the flash intensity of -0.6 (log cd · s/m2). Each data 
point represents the measured a-wave amplitude of an individual treated mouse. The group 
average of scAAV treated mice was significantly higher than the group average of ssAAV 
treated mice (p ≤ 0.027). (D) Comparison of mean rod photoreceptor response (a-wave 
amplitude) between ss and scAAV treatments over increasing flash intensities. Average a-wave 
amplitudes from the scAAV treated mice were significantly greater than the ssAAV treated mice 
at all intensities (p ≤ 0.027). Error bars, ±SEM. 
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Fig. 3 
 
 
 
Fig. 3. Restoration of photoreceptor morphology and PDE6 expression in Aipl1-/- retina 
following early AAV treatment. Aipl1-/- mice were treated at P2 and retinas were collected at 
P60 for immunocytochemistry and immunoblots. (A) Confocal images of retinal sections stained 
with indicated antibodies. Peanut agglutinin (PNA) (red) which stains the cone sheath is a cone 
marker. Cell nuclei were stained with DAPI (blue). Images were taken at x63 magnification. 
Scale bar, 20 µm. OS, outer segment; IS, inner segment; ONL, outer nuclear layer; INL, inner 
nuclear layer. (B) Photoreceptor cell nuclei quantification of ssAAV and scAAV treated retina 
using retinal sections stained with DAPI. scAAV treatment showed significantly higher ONL 
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cell counts than ssAAV treated retina (p ≤ 0.005). Error bars, ±SEM. (C) Western blots of retinal 
extracts from ssAAV and scAAV treated animals with indicated antibodies. Untreated Aipl1-/- 
(lane 5), wild-type (lane 6), and transgenic hAipl1 (lane 7) retina served as controls. PKCα 
expressed in bipolar cells, is a loading control.  
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Fig. 4 
 
 
 
Fig. 4. Restoration of photoreceptor ultrastructure following early AAV treatment. (A) 
Semithin light micrographs of P35 Aipl1-/- retina following treatment at P2 with ssAAV or 
scAAV. Semithin sections from a P35 Aipl1+/+ retina are shown for comparison. Scale bar, 20 
µm. RPE, retinal pigmented epithelium; OS, outer segment; IS, inner segment; ONL, outer 
nuclear layer. (B) Electron micrographs at x2200 (top panel) and x8900 (bottom panel) 
magnification. RPE, retinal pigmented epithelium; MV, microvilli; OS, outer segment; IS, inner 
segment. Scale bars, 5 µm (top panel) and 1 µm (bottom panel).  
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Fig. 5 
 
Fig. 5. Vision-dependent behavior is restored in Aipl1-/- mice following early ss- or sc-AAV 
treatment. Mice received treatment at P2 and were tested at P60 with the Morris water maze. 
Age-matched untreated Aipl1-/- and Aipl1+/+ groups served as controls. The time to reach the 
escape platform was recorded and reported as group averages. Treatment with both AAVs 
restored vision-dependent behavior to wild-type Aipl1+/+ levels (p > 0.05), which were 
significantly different from untreated Aipl1-/- mice (**p < 0.001, ANOVA with Tukey-Kramer 
HSD post-hoc test). Error bars, ±SEM. 
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Fig. 6 
 
Fig. 6. Light-dependent photoresponses in Aipl1-/- mice following late administration of 
AAV-mediated gene replacement therapy. ERG responses were recorded at P30, following 
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injection at P10. ERG tracings were recorded under (A) dark-adapted and (B) light-adapted 
conditions at the indicated flash intensities. (C) A-wave amplitudes of individual mice in ssAAV 
and scAAV treated groups, derived from ERG recordings at -0.6 (log cd · s/m2) flash intensity. 
All scAAV treated eyes showed higher a-wave amplitudes than ssAAV treated eyes. 
Additionally, the group average of scAAV treated mice was significantly higher than the group 
average of ssAAV treated mice (p ≤ 0.0006). Quantitative analysis of mean (D) a-wave and (E) 
b-wave amplitudes showed significantly higher amplitudes in the scAAV treated group than the 
ssAAV treated group across all flash intensities under dark-adapted conditions (p ≤ 0.003). (F) 
Quantitative analysis of mean b-wave amplitudes from ERGs recorded under light-adapted 
conditions. Higher photopic responses were elicited from scAAV treated eyes compared to 
ssAAV treated eyes (p ≤ 0.014). Error bars, ±SEM. 
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Fig. 7 
 
Fig. 7. Photoreceptor morphology of Aipl1-/- retina following late administration of AAV-
mediated gene replacement. Aipl1-/- mice were treated at P10 and retinas were collected at P35 
for immunocytochemistry. (A) Confocal images of retinal sections stained with indicated 
antibodies. Peanut agglutinin (PNA) (red) is used as a cone marker. Cell nuclei are stained with 
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DAPI (blue). Images were taken at x63 magnification. Scale bar, 20 µm. OS, outer segment; IS, 
inner segment; ONL, outer nuclear layer; INL, inner nuclear layer. (B) Quantification of 
photoreceptor cell nuclei showed significantly greater nuclei in scAAV compared to ssAAV 
treated retina (p ≤ 0.0000001). Error bars, ±SEM. (C) Western blots of ssAAV (lanes 1-5) and 
scAAV (lanes 6-10) treated retina. Untreated Aipl1-/- (lane 11), wild-type (lane 12), and 
transgenic hAipl1 (lane 13) retina serve as controls. PKCα expressed in bipolar cells, is a loading 
control.  
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Fig. 8 
 
Fig. 8. Vision-dependent behavior is restored to Aipl1-/- mice exclusively by scAAV 
treatment. Mice were tested at P35 after AAV administration at P10 with the Morris water maze 
assay. The mean time of scAAV treated mice was similar to wild-type Aipl1+/+ mice (p > 0.05), 
and both were significantly lower than untreated Aipl1-/- and ssAAV treated mice (*p < 0.01 at 
group indicated comparisons, ANOVA with Tukey HSD). The mean time of ssAAV treated 
mice was not significantly different from untreated Aipl1-/- mice (p > 0.05). Error bars, ±SEM. 
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Supplementary Fig. 1 
 
Supplementary Fig. 1. Rate of retinal degeneration and vision loss in the Aipl1-/- mouse. 
(A) Immunostaining of Aipl1+/+ and Aipl1-/- retina at postnatal day 2 (P2), P8, P10, and P35 
with propidium iodide, a marker of cell death. Arrowheads indicate photoreceptor cell death in 
Aipl1-/- retina, which began at P8 and was clearly evident at P10. Images were taken at x40 
magnification. Scale bar, 20 µm. ONL, outer nuclear layer; INL, inner nuclear layer.  
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Supplementary Fig. 2 
 
Supplementary Fig. 2. Photoreceptor rescue spanned the retina following both early and 
late administration of scAAV. Hematoxylin and eosin (H&E) sections of Aipl1-/- retina at P35 
following scAAV treatment at (A) P2, and (B) P10. An untreated contralateral eye is shown for 
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comparison. Images of the eyecup were taken at x10 and photomerged, and at x40 magnification 
for inset images. Scale bar, 20 µm.  
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Supplementary Fig. 3 
 
Supplementary Fig. 3. Protein expression at P35 following early administration of ssAAV 
and scAAV. Western blots of retina from Aipl1-/- mice at P35 following treatment at P2, probed 
with the indicated antibodies. Representative samples from three ssAAV (lanes 1-3) and scAAV 
(lanes 4-6) treated mice are shown. Untreated Aipl1-/- (lane 7), wild-type (lane 8), and transgenic 
hAipl1 (lane 9) served as controls. PKCα expressed in bipolar cells, is a loading control. 
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Supplementary Fig. 4 
 
Supplementary Fig. 4. Longitudinal ERG responses recorded from a P10 treated scAAV 
mouse. ERG recordings from a representative individual mouse at (A) P30 and (B) P60 show 
maintenance of dark-adapted and light-adapted photoresponses, achieved with late 
administration of scAAV treatment. Dark-adapted ERG responses were elicited with the 
indicated flash intensities of -3.6, -1.6, -0.6, and 0.4 log (cd · s/m2). Light-adapted ERG 
responses were elicited with a flash intensity of 0.4 log (cd · s/m2). 
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Chapter 3 
 
P351Δ12 Aipl1 mutation: a model of cone-rod dystrophy 
 
Abstract 
Defects in aryl hydrocarbon receptor interacting protein-like1 (Aipl1) are typically 
associated with the most severe of inherited retinal degenerations, Leber congenital amaurosis 
(LCA). Pre-clinical rescue studies of Aipl1-null mice, a model for LCA that has the most rapid 
retinal degeneration of any mouse model, have mainly served as proof-of-principle to 
demonstrate that even the most severe of retinal dystrophies can be rescued. However, reports of 
Aipl1 defects associated with less severe IRDs, such as retinitis pigmentosa (RP) and cone-rod 
dystrophy (CORD), highlight the potential for Aipl1 to be a candidate gene for future AAV-
mediated gene therapy clinical trials. Specifically, the P351Δ12 hAipl1 mutation, a defect in the 
C-terminal primate-specific ‘hinge’ region of AIPL1, has been linked to autosomal dominant 
CORD and juvenile RP. Autosomal dominant retinal degeneration has not been otherwise 
associated with Aipl1, and is important to evaluate since it indicates that AAV-mediated gene 
replacement may not be helpful despite the slower degeneration associated with CORD and RP. 
Other mutations have also been reported in the AIPL1 hinge region, although the function of this 
primate-specific region remains unknown. 
We sought to examine the effects of the P351Δ12 hAipl1 mutation by generating a 
transgenic mouse with this mutation. As compared to a transgenic line expressing wildtype 
hAipl1 under the same mCrx promoter construct, mutant P351Δ12 hAipl1 mice demonstrated a 
CORD phenotype with early defects in cone-mediated vision and subsequent degeneration. The 
mCrx promoter is active in both rods and cones as early as embryonic day 12.5 (E12.5). A 
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dominant phenotype was observed in double transgenic animals expressing both mutant 
P351Δ12 hAIPL1 and WT hAIPL1, in agreement with the autosomal dominant inheritance 
observed in patients with the P351Δ12 hAipl1 mutation. Interestingly, we were able to rescue 
cone-mediated vision in P351Δ12 hAipl1 mice following AAV-mediated gene delivery of WT 
hAipl1 despite the dominant phenotype of the P351Δ12 mutation. Our transgenic P351Δ12 
hAipl1 mouse offers a novel model of Aipl1-CORD, with distinct defects from both the Aipl1-
null mouse mimicking LCA and the Aipl1-hypomorphic mice mimicking a slow progressing RP. 
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Introduction 
 Inherited retinal degeneration (IRD) is a group of blinding disorders affecting 
approximately 1 in 3000 people (Daiger et al., 2007). Multiple forms of inherited retinal 
degenerations exist with varied onset, symptoms, severity, and progression of disease. Leber 
congenital amaurosis (LCA) shows the earliest onset and greatest severity of inherited retinal 
dystrophies, presenting in early infancy with severe visual impairment and absent or markedly 
reduced rod and cone-mediated electroretinograms (ERG). Other IRDs such as retinitis 
pigmentosa (RP) and cone-rod dystrophy (CORD) show a greater variability in onset and rate of 
disease progression. Additionally, while LCA patients show severe defects early on in both rod- 
and cone-mediated vision, RP patients present with night blindness as the first visual impairment 
alongside normal visual acuity. In contrast, CORD patients initially present with decreased visual 
acuity, central vision loss, and dyschromatopsia, with progressive loss in peripheral, rod-
mediated vision. Successful clinical trials of gene replacement therapy improving visual function 
in LCA patients with defects in retinal pigmented epithelium-specific 65 kDa protein (Rpe65) 
has garnered attention to finding another candidate gene for treatment. Outside of the unusual 
circumstance of Rpe65-LCA, where patients show significant visual defects disproportionate to 
slow photoreceptor loss (Jacobson et al., 2005; Cideciyan 2010), the slower disease progression 
of CORD and RP may indicate a larger therapeutic window in patients.  
One such candidate gene for future AAV-mediated gene replacement is aryl hydrocarbon 
receptor interacting protein-like 1 (Aipl1). Although defects in Aipl1 are mainly associated with 
autosomal recessive LCA, sporadic reports have linked Aipl1 to less severe IRDs of CORD, 
juvenile RP, non-early onset RP, and later onset retinal degeneration (Sohocki et al., 2000b; 
Vallespin et al., 2007; Walia et al., 2010; Jacobson et al., 2011). These cases point to a subset of 
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Aipl1 patients who may be better candidates for gene replacement therapy due to a slower 
disease progression. Several non-LCA Aipl1 cases are linked to defects in the C-terminal 
primate-specific proline-rich region of Aipl1 (Fig. 1A, grey box), specifically mutations P351∆12 
(cDNA del1053-1064) and A336∆2 (cDNA del1008-1009) (Sohocki et al., 2000a; Sohocki et al., 
2000b). P351Δ12 hAipl1 has been associated with autosomal dominant CORD and juvenile RP. 
Autosomal dominant disease has not been otherwise reported with Aipl1, and is important to 
examine because it indicates a dominant negative mechanism of dysfunction differing from the 
loss of function observed with truncation mutation W278X. Autosomal dominance is also 
clinically important to examine as it potentially indicates that AAV-mediated gene replacement 
would not be helpful for the P351Δ12 hAipl1 mutation, despite a slower disease progression.  
Lastly, it may shed light on the function of the C-terminal primate-specific proline-rich hinge 
region of human Aipl1. The function of the hinge region in hAipl1 remains unknown, although 
the additional size provided by this 56 aa region has been advantageously used to differentiate 
mouse and exogenously introduced human Aipl1 in transgenic and AAV-mediated rescue studies 
(Tan et al., 2009; Kirschman et al., 2010; Sun et al., 2010).  
 The aim of this study was to examine the effects of the patient mutation, P351Δ12 
hAipl1. We sought to characterize the visual dysfunction associated with this mutation, to 
evaluate whether this mutation leads to retinal degeneration in a dominant fashion, and to 
attempt to rescue the visual dysfunction with AAV-mediated gene replacement. To do so, we 
generated transgenic mice expressing this hinge region mutation alongside control mice 
expressing wildtype hAipl1, both expressed under the mouse Crx (cone-rod homeobox) 
promoter.  
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Materials and Methods 
Animals 
All experiments involving animals described in this stdy were approved by the Institutional 
Animal Care and Use Committee at West Virginia University (WVU). Mice were maintained 
under 12-h light / 12-h dark light cycles with food and water provided ad libitum.  
Generation of transgenic hAipl1 mice 
Full length hAipl1 was amplified from a human retinal cDNA library and engineered by 
polymerase chain reactions (PCR) with an N-terminal Flag epitope tag and cloned under the 2.3 
kb mCrx promoter (Furukawa et al., 2002) using a mCrx-LacZ vector generously provided by 
Dr. Takahisa Furukawa (Osaka Bioscience Institute, Osaka, Japan). The P351Δ12 hAipl1 
mutation was introduced through amplification with reverse primer 5’ 
CAGCTCTGCAGATGGTGCTGTGGGTGGCTCTGTGGATGACTGTGC 3’, introducing a 12 
bp deletion at nucleotide position 1053-1064, and also cloned under the mCrx promoter. All PCR 
reactions were performed with Phusion GC DNA polymerase master mix (Finnymes, Thermo 
Scientific, Lafayette, CO, USA), following manufacturer instructions for cycling conditions and 
the sequence verified using Big Dye Terminator ready reaction kit (Perkin Elmer, Waltham, MA, 
USA). mCrx-hAipl1 (wildtype) and mCrx-P351Δ12 hAipl1 (mutant) was digested, purified using 
the Wizard SV Gel and PCR Clean-Up system (Promega, Madison, WI, USA), and injected into 
the pronuclei of oocytes from superovulated FVB/N females (WVU Transgenic Animal Core 
Facilities) followed by implantation into pseudopregnant females. Wildtype- and mutant 
P351Δ12 hAipl1 transgenic founders were identified through PCR primers amplifying an 750 bp 
fragment spanning the 3’ region of the mCrx promoter and 5’ region of hAipl1, using forward 
primer 5’ CTGGTTGCAGGCAAGAGT 3’ and reverse primer 5’ 
78 
 
GTCCGCTCCTCATCACATTT 3’. Founders were backcrossed into wildtype 129sv mice to 
overcome the Pde6brd1 mutation present in the FVB strain, and further backcrossed with Aipl1 
knockout mice in a mixed C57Bl/129sv background described previously (Ramamurthy et al., 
2004; Ku et al., 2011).  
Electroretinographic (ERG) analysis 
Mice were dark-adapted overnight prior to testing. Eyes were topically dilated with a 1:1 mixture 
of tropicamide: phenylephrine hydrochloride. For ERG testing, mice were placed on a heated 
platform with continuous flow of isoflurane anesthesia through a nose cone (1.5% isoflurane 
with 2.5 liters per minute (lpm) oxygen flow rate). A reference electrode was placed 
subcutaneously in the scalp. ERG responses were recorded from both eyes with silver wire 
electrodes placed on each cornea, with contact being made with a drop of hypromellose solution 
(2% hypromellose in PBS) (Gonioscopic Prism Solution, Wilson Ophthalmic, Mustang, OK, 
USA). Rod dominated responses were elicited in the dark with flashes of LED white light at 
increasing flash intensities. Light-adapted cone responses were elicited with white light flashes 
in the presence of a 30 cd/m2 rod-desensitizing white background light. ERGs were performed on 
the UTAS Visual Diagnostic System with BigShot Ganzfeld with UBA-4200 amplifier and 
interface, and EMWIN 9.0.0 software (LKC Technologies, Gaithersburg, MD, USA).   
Optokinetic responses (OKR)  
Analysis of mouse optokinetic responses were examined using the OptoMotry system 
(CerebralMechanics, Inc., Lethbridge, Alberta, Canada). Briefly, the system consists of a square 
array of four computer monitors and an elevated platform on which a freely moving mouse is 
placed. The mouse is observed from above through a camera mounted at the top. The system was 
also adapted for measuring optokinetic responses at scotopic light levels, by surrounding the 
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platform with a large cyclinder of neutral density filters (E-Colour #211 0.9 ND, Rosco 
Laboratories, Inc., Glendale, CA, USA), and observing the mouse using NightVision camera 
mode (Sony, San Diego, CA, USA) under a circular array of 6 infrared lights (OSRAM Opto 
Semiconductors, Inc., Sunnyvale, CA, USA), as described previously (Kolesnikov et al., 2010). 
The computer monitors form a virtual cylinder of rotating sine-wave vertical gratings which 
randomly rotates clockwise or counterclockwise as controlled by the OptoMotry computer 
program. Mice reflexively respond to the rotating gratings by turning their head in the 
corresponding direction of the grating. The observer registers the mouse behavior through the 
two-alternative forced-choice protocol (Umino et al., 2006), picking either clockwise or 
counterclockwise, and the computer program changes the grating spatial frequency (in the visual 
acuity mode) using the random staircase paradigm, until the threshold is reached at 70% of the 
trials (Umino et al., 2008). Visual acuity was defined as the threshold for spatial frequency of 
gratings and measured at the optimal speed (Sp) of 12.0 deg/s (Umino et al., 2008). In this mode, 
spatial frequency (Fs) was randomly changed by the computer protocol, starting from 0.042 
cyc/deg, until threshold or maximal spatial frequency was determined. Temporal frequency (Ft) 
was automatically adjusted by the computer program based on the equation, Ft = Sp x Fs. Lastly, 
the OptoMotry apparatus can measure threshold spatial frequency from each eye independently, 
in a freely moving mouse without any suturing (Douglas et al., 2005). This is because the 
optokinetic tracking response is elicited when motion is in the temporal-to-nasal direction of the 
visual field. Thus, counterclockwise grating rotation will drive tracking through the right eye and 
elicit a counterclockwise optokinetic response; whereas clockwise grating rotation drives 
tracking through the left eye. This property of the apparatus was taken advantage of to 
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independently measure treated and untreated eyes in mice receiving AAV-mediated gene 
delivery.  
Immunoblotting, immunohistology, and morphometric analysis 
Mice were euthanized by CO2 inhalation and eyes were enucleated. For immunoblots, flash 
frozen retinal samples dissected from enucleated eyes were sonicated in phosphate buffered 
saline (PBS,137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4·7H2O, 1.4 mM KH2PO4, with 
protease inhibitors and 10 mg/ml dithiothreitol (DTT)). Protein concentrations were measured 
using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Inc., Pittsburgh, PA, USA). 150 
µg total protein samples were resolved on a 8.7 cm long 10% polyacrylamide SDS-PAGE 
resolving gel (Criterion Midi format, Bio-Rad, Hercules, CA, USA), or on a longer format 16 cm 
long 9% polyacrylamide SDS-PAGE resolving gel where specified (Hoefer, Inc., San Francisco, 
CA, USA), and transferred onto polyvinylidene difluoride membranes (Immunobilon-FL, 
Millipore, Billerica, MA, USA). Membranes were blocked with blocking buffer (Rockland Inc., 
Gilbertsville, PA, USA) for 30 min at room temperature, and incubated with the indicated 
primary antibodies. Blots were washed in PBST (PBS with 0.1% Tween-20) twice for 20 min 
and incubated in secondary antibody, goat anti-rabbit or goat anti-mouse IRDye 680 (LI-COR 
Biosciences, Lincoln, NE, USA) for 30 min at room temperature. After 3 washes with PBST, 
membranes were scanned using the Odyssey Infrared Imaging System (LI-COR Biosciences, 
Lincoln, NE, USA), and bands quantified using Odyssey Infrared Imaging System software.  
For immunohistochemical studies, eyes were immersed in 4% paraformaldehyde fixative 
for 15 min prior to removal of the anterior segments and lens. Eyecups were fixed for an 
additional 2 h, washed in PBS for 20 min, incubated in 10% sucrose/PBS for 1 h at room 
temperature, and transferred to 20% sucrose/PBS for overnight incubation at 4°C. Eyes were 
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then incubated in 1:1 mixture of 20% sucrose in PBS:OCT (Cryo Optimal Cutting Temperature 
Compound, Sakura, Torrance, CA, USA) for 1 h, and flash frozen in OCT. Cryosectioning was 
performed with a Leica CM1850 Cryostat, and serial retinal sections of 14 µm thickness were 
mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA, USA). Retinal sections 
mounted on slides were washed with PBSTx (PBS with 0.1% TritonX-100), and incubated for 1 
hr in blocking buffer (PBS with 5% goat sera, 0.5% TritonX-100, 0.05% sodium azide). Retinal 
sections were incubated with primary antibody for 2-3 hrs, followed by three 10 min washes with 
PBSTx before incubation with secondary antibody (Alexa Fluor-488 or Alexa-Fluor 568, 
Invitrogen, Carlesbad, CA, USA) for 30 min. The nuclear marker, 4’,6-diamidino-2-
phenylindole (DAPI, Invitrogen, 1:5000 dilution) was added for 10 min, and washed with  
PBSTx before mounting with Prolong anti-fade reagent (Invitrogen) and coverslipping. Slides 
were viewed and imaged on a laser scanning confocal (Zeiss LSM 510) on a Zeiss LSM 
AxioImager Z1 microscope.  
The following primary antibodies were used at the indicated dilutions: Human AIPL1 
(1:2500) (Ramamurthy et al., 2004), human and mouse AIPL1 (1:2500) (gift from Dr. Tiansen 
Li, National Eye Institute, Bethesda, MD), PDE6αβγ (MOE) (1:2000) (CytoSignal Inc., Irvine, 
CA, USA), PDE6β (1:1000) (Affinity BioReagents, Golden, CO, USA), cone PDEα’ (1:1000) 
(Kirschman et al., 2010), mouse cone arrestin (1:1000) (gift from Dr. Wolfgang Baehr, 
University of Utah, Salt Lake City, UT), guanylyl cyclase-E (GC-E) (gift from Dr. Baehr), 
red/green opsin (1:1000) (Chemicon, Millipore, Billerica, MA, USA). Rhodamine peanut 
agglutinin (PNA) (1:500) (Vector Laboratories, Inc., Burlingame, CA, USA) and DAPI (1:5000) 
(4’,6-diamidino-2-phenylindole, Invitrogen, Grand Island, NY, USA) were also used in 
immunocytochemistry. 
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Histologic, semithin sections, and transmission electron microscopy 
For light and transmission electron microscopy, mice underwent transcardial fixation perfusion 
(Tissue Processing and Analysis Core, WVU) prior to retinal sample collection. Briefly, mice 
were deeply anesthetized with ketamine/xylazine (100 mg/kg ketamine, 10 mg/kg xylazine) prior 
to perfusion. The animal was perfused through the ascending aorta with a cannula attached to a 
perfusion pump (Harvard Apparatus, Holliston, MA, USA) with a pressure-relieving incision 
made in the right atrium. A vascular rinse was conducted prior to perfusion fixation (1% 
paraformaldehyde, 1.25% glutaraldehyde, 0.1 M sodium cacodylate buffer, pH 7.5). Enucleated 
eyes were further fixed (2% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M cacodylate buffer, 
pH 7.5) for 30 min prior to dissection and removal of the anterior segment and lens, and 
extensively fixed for 48 hours at room temperature. The fixed eyecup was dissected into 6-8 
wedge-shaped pieces. Wedges were dehydrated in a graded ethanol series, then embedded in 
Polybed 812 (PolySciences, Inc., Warrington, PA, USA). Semi-thin (1 μm) sections were 
collected onto glass slides, stained with toluidine blue, and visualized using a Zeiss Axioimager 
2 microscope equipped with EC Plan-Neofluar 40x (N.A. 0.75) and 100x (1.3 N.A.) objectives to 
identify best rescued areas. Thin sections (ca. 80 nm) from selected wedges were collected onto 
nickel grids, stained with 2% uranyl acetate and lead citrate, and imaged using an FEI Morgagni 
transmission electron microscope at 80 kV. 
Generation of recombinant AAV vectors 
Full-length human Aipl1 was amplified from pAAV-RKp-hAipl1 plasmid (Sun et al., 2010) with 
primers that engineered flanking Kpn-I and Eag-I sites, and cloned into the scAAV packaging 
vector (University of Florida, Retinal Gene Therapy Group), to generate the sc-RKp-hAipl1 
plasmid. All PCR amplifications were performed with Phusion GC DNA polymerase master mix 
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(Finnymes, Thermo Scientific, Lafayette, CO, USA), following manufacturer instructions for 
cycling conditions. All plasmids were sequenced with the Big Dye Terminator ready reaction kit 
(Perkin Elmer, Waltham, MA, USA). The sc-RKp-hAipl1 plasmid was used to produce the self-
complementary AAV8 Y733F surface-exposed tyrosine residue capsid mutant (scAAV2/8-
Y733F-RKp-hAipl1) viral vector described previously (Ku et al., 2011) with a viral titer of 1.2 x 
1013 viral particles per mL.  
Subretinal injection 
Transgenic mice injected at postnatal day 10 (P10) and P15 were placed under general anesthesia 
with an intraperitoneal injection of ketamine (90 mg kg-1) / xylazine (9 mg kg-1) and received a 
drop of topical anesthetic, proparacaine hydrochloride (0.5%, Akorn, Lake Forest, IL, USA), 
followed by a drop of dilation solution, consisting of a 1:1 mixture of tropicamide (1%, Alcon, 
Fort Worth, TX, USA) : phenylephrine hydrochloride (2.5%, Bausch and Lomb, Tampa, FL, 
USA).  For injection into mice prior to eyelid opening, an incision was made along the natural 
future eyelid line with surgical vannas scissors. A small incision was then made in the sclera just 
outside the pupillary margin with a 36-gauge needle. Viral solution was injected into the 
subretinal space using a pulled glass pipette attached to a pneumatic injector (MINJ-PD, Tritech 
Research, Los Angeles, CA, USA) through a transcorneal approach (Matsuda and Cepko 2004). 
Each animal received 1.25 µl of AAV in the right eye, and no injection in the untreated 
contralateral eye. Visualization during injection was aided by the addition of 0.1% fluorescein 
(100 mg ml-1 AK-FLUOR, Alcon, Fort Worth, TX, USA) to the viral solutions.  
Statistical analyses 
Statistical analyses were conducted on GraphPad Prism6 software (GraphPad Software, Inc., La 
Jolla, CA, USA), using two-tailed unpaired t-tests for two group comparisons, and ANOVA with 
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Bonferronni correction for multiple group comparisons. 
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Results 
Generation of wildtype- and mutant P351Δ12 hAipl1 mice  
To examine the effects of the P351Δ12 hAipl1 mutation, a 12 bp, 4 aa in-frame deletion 
in the C-terminal proline-rich region of hAIPL1 (Fig. 1A), transgenic P351Δ12 hAipl1 mice were 
generated. A control transgenic line expressing wildtype hAipl1 (designated WT hAipl1) was 
generated alongside the transgenic mutant line. Both wildtype and mutant transgenes were driven 
by the 2.3 kb mCrx promoter (Fig. 1B), active beginning at embryonic day 12.5 (E12.5) in retinal 
progenitor cells (Furukawa et al., 2002). We chose the mCrx promoter due to its early activity 
and because it drives expression in both rod and cone photoreceptors (Furukawa et al., 2002), an 
important property since cone cell death occurs in the absence of Aipl1 in a previous transgenic 
model expressing hAipl1 (Kirschman et al., 2010) driven by Nrl (neural retina-specific leucine 
zipper) (pNrl-hAipl1), a known rod-specific promoter (Akimoto et al., 2006; Kirschman et al., 
2010; Kautzmann et al., 2011). Transgenic WT hAipl1 mice were backcrossed into mouse Aipl1-
null mice to generate WT hAipl1 (mAipl1+/-) (designated as WT hAipl1 (+/-)) and WT hAipl1 
(mAipl1-/-) (designated as WT hAipl1 (-/-)) littermates. The same breeding scheme was 
conducted with the experimental P351Δ12 hAipl1 transgenic mice. Mice from both lines were 
normal, healthy, and fertile, with no gross morphological abnormalities. All comparisons 
subsequently made are between control WT hAipl1 and experimental P351Δ12 hAipl1 in a 
mAipl1-null background (WT hAipl1 (mAipl1-/-) and P351Δ12 hAipl1 (mAipl1-/-)) unless 
otherwise explicitly stated. 
Protein expression of P351Δ12 hAIPL1 was comparable to WT hAIPL1 (Fig. 2). To note, 
the mobility of mutant P351Δ12 hAIPL1 was shifted, running slightly below WT hAIPL1 in 
immunoblots. Additionally, with the flag-epitope tag, both WT and P351Δ12 hAipl1 run slightly 
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higher than non-tagged hAipl1. Expression of wildtype and mutant hAIPL1 is greater than 50% 
of endogenous mAIPL1 levels, as quantified through the use of an AIPL1 antibody that 
recognizes human and mouse AIPL1 equally (gift from Dr. Tiansen Li). This is equivalent to 
mAipl1 heterozygous mice (mAipl1+/-) which show no visual dysfunction or retinal degeneration 
(Ramamurthy et al., 2004).  
 
P351Δ12 hAipl1 mice show drastically reduced photopic responses and reduced scotopic 
responses at an early age 
 Electroretinography (ERG) was performed at P15, shortly after eyelid opening in mice, to 
evaluate whether the P351Δ12 hAipl1 mutation leads to visual deficits. P351Δ12 hAipl1 (mAipl1-
/-) mice had markedly reduced photopic, cone-mediated ERG responses, of approximately 40% 
of ERG responses from WT hAipl1 (mAipl1-/-) mice (p < 0.0005 at all light intensity 
comparisons; log 0.4 WT hAIPL1 mean = 73.20 ± 6.96 µV, n=5; log 0.4 P351Δ12 hAIPL1 mean 
= 30.50 ± 4.94 µV, n=4; log 0.7 WT hAIPL1 mean = 95.80 ± 6.02 µV, n=5; log 0.7 P351Δ12 
hAIPL1 mean = 42.50 ± 7.00 µV, n=4; log 0.9 WT hAIPL1 mean = 110.0 ± 6.00 µV, n=5; log 
0.9 P351Δ12 hAIPL1 mean = 47.00 ± 10.31 µV, n=4) (Fig. 3A, C). Scotopic, rod-mediated ERG 
responses were also reduced, although less drastically, to approximately 50-70% of WT hAipl1 
ERG levels, with greater reduction at lower flash intensities (Fig. 3B, C) (p values as indicated, 
ranging from p < 0.05 to p < 0.0005). We therefore examined the intensity-response relationship 
from scotopic ERG measurements and found that rods from mutant P351Δ12 hAipl1 mice had a 
higher half-saturating light intensity compared to WT hAipl1 (Fig. 3D), indicating reduced 
sensitivity.  
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P351Δ12 hAipl1 mice show accelerated decline of photopic responses and gradual decline of 
scotopic responses 
 To evaluate whether the visual defect was progressive or stationary, we measured ERG 
responses in animals of increasing age. P351Δ12 hAipl1 mice showed a rapid decline in photopic 
cone-mediated ERG responses decreasing to approximately 10% by P60. The 10% of WT hAipl1 
photopic response comes from several P351Δ12 hAipl1 mice that showed small phototopic 
responses, whereas the other half of the mutant mice had completely abolished photopic ERG 
responses. This trend was similar at P90-P120, resulting in approximately 5% of WT hAipl1 
photopic response.  
Scotopic, rod-mediated ERG responses also decreased albeit at a much slower rate (Fig. 
4, dashed line). The largest decline in scotopic response in P351Δ12 hAipl1 mice was observed 
between P60 and P90, where 49% of WT hAipl1 response decreased to 37% and remained stable 
until P360 (P360 data not shown).  
 
P351Δ12 hAipl1 mice show decreased visual behavior  
To determine whether decreased ERG responses affected functional vision in mutant 
P351Δ12 hAipl1 mice, we performed behavioral tests based on the ability of the mouse to 
reflexively track computer-generated sinusoidal gratings (Douglas et al., 2005). Visual acuity is 
evaluated by measuring the threshold (maximal) spatial frequency of the gratings that elicits an 
optokinetic response from the mouse. Measurements are conducted under photopic and scotopic 
conditions (Kolesnikov et al., 2010). At P30, P351Δ12 hAipl1 mice showed significantly lower 
optokinetic responses under photopic conditions (Fig. 5A, photopic left) (p = 0.0184; WT mean 
= 0.5339 ± 0.03541 cyc/deg, n=5; P351Δ12 mean = 0.3298 ± 0.0045 cyc/deg, n=2). Under 
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scotopic conditions, mutant mice showed a trend toward lower optokinetic responses than 
wildtype, however, a significant decrease was observed at only one scotopic background light 
intensity (Fig. 5A, scotopic right) (p = 0.036; WT mean = 0.4048 ± 0.02497 cyc/deg, n=5; 
P351Δ12 mean = 0.2882 ± 0.022 cyc/deg, n=2).  
Functional vision further decreased at P60, where the maximal spatial frequency that 
P351Δ12 hAipl1 mice respond to optokinetically was lower than that of WT hAipl1 mice, under 
all scotopic background light intensities (Fig. 5B, scotopic right) (p values as indicated, ranging 
from p < 0.05 to p < 0.0005). Although significantly decreased, some optokinetic response could 
still be elicited under scotopic conditions. This differed from measurements under photopic 
conditions, where mutant P351Δ12 hAipl1 mice showed no reliable optokinetic response (Fig. 
5B, photopic left) (p = 0.0006; WT mean = 0.4087 ± 0.04430 cyc/deg, n=6; P351Δ12 mean = 
0.1052 ± 0.0004861 cyc/deg, n=4). Additionally, we confirmed that photopic conditions used 
were specifically measuring cone-mediated visual behavior with cpfl1 mutant mice (generously 
provided Dr. Bo Chang, Jackson Labs), which lack photopic ERG responses due to a 
spontaneous mutation in cone phosphodiesterase 6 (cPDE6). Adult cpfl1 mice showed no 
reliable optokinetic response under photopic conditions (data not shown).  
 
Cone photoreceptor cell death and cone outer segment disorganization in P351Δ12 hAipl1 
mice. 
 Because of the observed defects in photopic vision, we examined cone outer segment 
morphology and cone photoreceptor cell death. At P17, early photoreceptor cell death was 
observed in retinal sections from P351Δ12 hAipl1 mice through propidium iodide (Fig. 6A, 
propidium iodide red), where strong staining indicate dead cells. A majority of dead cells were 
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located at the top edge of the outer nuclear layer (ONL) where cone cell nuclei typically reside. 
Some propidium iodide positive cells co-localized with red/green opsin (Fig. 6A, green), 
whereas non-co-localizing dead cells likely indicates blue cone cell death. Despite the observed 
cone cell death at P17, remaining cones showed intact cone outer segments of relatively 
comparable length to WT hAipl1 cones, as indicated by R/G opsin staining (Fig. 6A, R/G opsin, 
green, and Supplemental Fig. 1). However, by P35, cone arrestin staining (Fig. 6B, cArr red) 
showed cone outer segment shortening (white arrows indicate cone outer segments). 
 
P351Δ12 hAipl1 mice show decreased cone phosphodiesterase 6 and rod transducin α 
 Through immunocytochemistry, we observed that mutant P351Δ12 hAipl1 mice show 
decreased expression of cone PDEα’ early on at P15 (Fig. 7A), which was confirmed with semi-
quantitative immunoblotting (Fig. 7B). This decrease was specific to cone PDEα’, as levels of 
cone transducin α, another cone outer segment protein, were similar in mutant P351Δ12 
compared to wildtype hAipl1 mice (Fig. 7B). There is a possible decrease in GC-E in cones as 
observed through immunocytochemistry at P15 (data not shown) and P35 (Fig. 4B); however, 
this was not observed in immunoblots (Fig. 7B) due to the expression of GC-E in both rods and 
cones, where 97% of photoreceptors are rods in the mouse retina. Lastly, we observed a slight 
decrease in levels of rod transducin α (Fig. 7B), which may account for the decreased rod 
sensitivity and defects in rod-mediated vision observed at P15 (Fig. 2B, C, D).  
 
Gene delivery of WT hAipl1 into mutant P351Δ12 hAipl1 mice 
 To address whether the P351Δ12 hAipl1 mutation acts in a dominant fashion, we 
introduced WT hAipl1 into mutant mice through two means. First, we generated double 
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transgenic mice by crossing WT hAipl1 with P351Δ12 hAipl1 mice, which were both flag-tagged 
at the N-terminus of AIPL1 (Fig. 1B). Double transgenic mice which co-express WT and 
P351Δ12 hAIPL1 (blue and red waveforms) continue to show a defect in cone-mediated ERG 
responses, as compared to a littermate expressing WT hAIPL1 (black waveforms) (Fig. 8A, B). 
Rod-mediated scotopic ERG responses were also decreased in double transgenic mice as 
compared to their WT hAipl1 littermate, although ERG responses were slightly greater than 
previously observed in single transgenic P351Δ12 hAipl1 mice. However, a direct comparison 
was not possible as no single transgenic P351Δ12 hAipl1 mice were found in the litters analyzed. 
This may be explained by the observed protein levels where, in our single transgenic mice, 
mutant P351Δ12 hAIPL1 was slightly less (< 2-fold) than WT hAIPL1 in each respective 
transgenic line, whereas the amount of P351Δ12 hAIPL1 was approximately 5-fold less than the 
co-expressed WT hAIPL1 in double transgenic positive mice. 
The second method expressed a non-tagged WT hAIPL1 via AAV-mediated gene 
delivery into transgenic mutant P351Δ12 hAipl1 mice, using a previously published scAAV8-
Y733F-RKp-hAipl1 viral vector (Ku et al., 2011). We first administered gene delivery at P15 and 
observed rescue of photopic cone-mediated ERG responses (p = 0.0401; treated mean = 30.67 ± 
3.844 µV, n=3; untreated mean = 6.33 ± 6.33 µV, n=3), but not scotopic rod-mediated responses. 
We then administered gene delivery at P10 to ensure that lack of rod-meditated rescue was not 
due to early rod photoreceptor loss. However, P10 gene delivery of WT hAipl1 also did not 
improve rod-mediated ERG responses, although cone-mediated rescue was improved by earlier 
gene delivery at P10 over P15 (p = 0.0235; P10 treated mean = 62.0 ± 8.386 µV, n=3; P15 
treated mean = 30.67 ± 3.844 µV, n=3) (Fig. 9A, B). Rescue effects on cone-mediated ERG 
responses following one AAV treatment administered either at P10 or P15 were observed until 
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P130, the last tested age. Additionally, photopic ERG responses in rescued eyes did not change 
longitudinally between P30, the first ERG testing date, and P130, the last ERG age tested. Cone-
mediated visual behavior as measured through optokinetic responses was greater in treated eyes 
as compared to untreated eyes (p = 0.0105; treated eye mean = 0.4278 ± 0.09206 cyc/deg, n=4; 
untreated eye mean = 0.09625 ± 0.06172 cyc/deg, n=4) (Fig. 10).  
To resolve the difference we see in introduction of WT hAipl1 through AAV-mediated 
gene delivery as compared to genetic manipulation, protein expression of WT hAIPL1 was 
compared between the two methods. We observed a drastically greater expression of WT 
hAIPL1 in AAV-treated eyes as compared to double transgenic mice (Fig. 11). Although the WT 
hAIPL1 band could not be fully resolved from the Flag P351Δ12 hAIPL1 band in AAV-treated 
eyes, we estimate (non-tagged) WT hAIPL1 to be in at least 25-fold excess of mutant P351Δ12 
hAIPL1, whereas Flag WT hAIPL1 in double transgenic mice are about 5-fold excess of Flag 
P351Δ12 hAIPL1 (Fig. 11).  
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Discussion 
Our studies demonstrate that P351Δ12 hAipl1, a rare mutation reported in two probands, 
is associated with retinal degeneration of a CORD phenotype. The patients, however, had 
discordant diagnoses; one with CORD and the other with juvenile RP, although both were 
reported to have likely inherited the mutation in an autosomal dominant manner (Sohocki et al., 
2000b). Our transgenic P351Δ12 hAipl1 mouse model shows an early loss of cone-mediated 
vision and subsequent cone photoreceptor degeneration. We attribute cone defects to decreased 
cone PDE6α’, which despite lower expression levels, appeared to localize correctly prior to later 
cone outer segment disorganization and degeneration. Additionally, we observed decreased 
expression of guanylyl cyclase-E in cone photoreceptors through immunohistochemistry; 
however, due to the expression of GC-E in both rods and cones and the overwhelming number 
of rods in retina compared to cones, we were unable to confirm this in semi-quantitative 
immunoblots. Additionally, mutant mice showed early subtle defects in rod-mediated vision, 
particularly with decreased sensitivity, which may be associated with the observed decrease in 
rod transducin α. Despite this finding however, rod-mediated vision decreased at a very slow 
rate, plateauing around P120.  
Interestingly, through our double transgenic experiments, we observed that the P351Δ12 
hAipl1 mutation acted in a dominant fashion in that cone-mediated vision could not be rescued 
with genetic re-introduction of WT hAipl1. Expression levels of WT hAIPL1 and P351Δ12 
hAIPL1 in double transgenic positive mice were relatively comparable. This mimicks a 
heterozygous state of P351Δ12 hAipl1, similar to what would occur in the reported P351Δ12-
CORD and RP patients. Therefore, our mouse model which shows a CORD phenotype, 
confirms the dysfunction associated with the P351Δ12 hAipl1 mutation even in a heterozygous 
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state. The varying phenotypes between patients with this mutation remains unresolved, 
however, we speculate that it may be due to differences in ratios of WT to mutant AIPL1 
protein in rods and cones. 
Despite the autosomal dominant inheritance pattern in patients and the dominant-like 
phenotype observed in our double transgenic animals, cone-mediated vision was improved 
following AAV-mediated gene replacement of WT hAipl1 in mutant P351Δ12 hAipl1 mice. 
This is likely due to the high protein expression of WT hAIPL1 achieved in treated animals. 
Treated mutant mice however, did not show any appreciable improvement in scotopic rod-
mediated vision, despite the overwhelming amount of WT hAIPL1 protein expressed. This may 
be due to local retinal damage from AAV injections that negates any improvement that can be 
seen overall. Alternatively, it may suggest that the P351Δ12 hAIPL1 acts in a dominant 
negative fashion which cannot be overcome with excess WT hAIPL1 in rods, and implicates a 
difference in Aipl1 function in rods and cones that may be attributable to the AIPL1 hinge 
region. 
The function of the AIPL1 hinge region remains in question; however, our model clearly 
shows detrimental effects of mutations in this region. It is possible that the dominant negative 
effects of the P351Δ12 hAipl1 mutation are exerted through this C-terminal primate-specific 
region, as transgenic positive P351Δ12 hAipl1 in a mAipl1 heterozygous background (P351Δ12 
hAipl1 (mAipl1+/-)) show no visual dysfunction (Supplementary Fig. 2). However, whether the 
dominant negative effects stem from a negative interaction between wildtype and P351Δ12 
hAIPL1, or alternatively, mutant P351Δ12 hAIPL1 negatively interacting with other essential 
photoreceptor proteins remains to be determined. 
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Multiple pre-clinical AAV-mediated rescue studies of defects in aryl hydrocarbon 
receptor interacting protein like-1 (Aipl1) have been recently conducted on previously reported 
Aipl1 mouse models (Tan et al., 2009; Sun et al., 2010; Ku et al., 2011). Aipl1-null mice which 
show the most severe and rapidly progressing degeneration of all retinal dystrophy models, 
mimicks truncation mutation W278X, the most prevalent mutation in Aipl1-LCA patients 
(Sohocki et al., 2000a; Sohocki et al., 2000b; Dharmaraj et al., 2004; Testa et al., 2011). 
Successful rescue of Aipl1-null mice provided proof-of-principle demonstrating that if the most 
severe of retinal degenerations is rescued, other Aipl1 defects may potentially be treated (Tan et 
al., 2009; Sun et al., 2010; Ku et al., 2011). However, the practical clinical target would likely be 
a less severely implicated Aipl1 mutation. Our novel transgenic P351Δ12 hAipl1 mouse offers a 
model to study Aipl1-CORD patients, and while these patients are rare, may benefit from gene 
replacement therapy. 
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Figures 
Fig. 1 
 
Fig. 1. The P351∆12 hAipl1 mutation interrupts a putative PxxP motif in the C-terminal 
proline-rich hinge region of hAIPL1. (A) The 12 bp deletion (blue arrow, underline, and box) 
results in a 4 amino-acid in-frame deletion, eliminating 1 of 5 potential PxxP motifs (black 
underline) present in the C-terminal proline-rich, primate-specific region (grey box) of hAipl1. 
(B) Transgenic mice were generated expressing either N-terminal Flag-tagged wildtype hAipl1 
(control transgenic line) or Flag-tagged P351∆12 hAipl1 (experimental line) under the 2.3 kb 
mCrx promoter. 
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Fig. 2 
 
Fig. 2. Expression of Flag-P351∆12 hAIPL1 is comparable to Flag-wildtype (WT) hAIPL1. 
Immunoblots of P10 retinal lysates from transgenic WT hAipl1 and P351∆12 hAipl1 mice 
probed with anti-AIPL1 that recognizes both mouse and human AIPL1 equally (gift from Dr. 
Tiansen Li). Equal amounts of protein were loaded for each sample (150 μg). mAIPL1: mouse 
AIPL1, hAIPL1: human AIPL1, Tg: transgenic hAIPL1.  
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Fig. 3 
 
Fig. 3. Mice with P351∆12 hAipl1 mutation show an early dramatic decrease in photopic 
vision and defects in scotopic vision. Families of representative ERG responses from postnatal 
day 15 (P15) wildtype hAipl1 and mutant P351∆12 hAipl1 mice, as recorded under (A) photopic 
and (B) scotopic conditions at indicated log intensity (cd · s / m2) flashes. (C) Comparison of 
mean cone and rod photoreceptor responses (a-wave amplitudes) between WT (white bar; n=5) 
and P351∆12 hAipl1 (grey bar; n=4). Average a-wave amplitudes (± SEM) from WT hAipl1 
mice were significantly different from P351∆12 hAipl1 mice at all photopic and scotopic flash at 
indicated scotopic flash intensities. P values are indicated as follows: *P < 0.05, ** P < 0.005, 
*** P < 0.0005. (D) Intensity-response relationship for scotopic a-wave amplitude, where data 
was fitted with hyperbolic function (Fulton and Rushton 1978), A = Amax ((I
n) / ( In + Inh   )), 
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where Amax is the maximal a-wave amplitude, n is the Hill coefficient, and Ih is the half-
saturating light intensity. This curve fit yielded scotopic a-wave half-saturating light intensities 
of 0.03346 ± 0.003360 cd · s / m2 (WT hAipl1, n=5) and 0.05774 ± 0.004798 cd · s / m2 
(P351∆12 hAipl1, n=4). Data points are mean ± SEM.  
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Fig. 4  
 
Fig. 4. Accelerated loss of photopic ERG responses with slower decline in scotopic ERG 
responses in P351∆12 hAipl1 mutant mice. ERG responses over time (from P15 to P120), as 
expressed as the ratio of (P351Δ12 hAipl1 / WT hAipl1) a-wave amplitudes, obtained from 
measurements taken with 2.5x10-2 cd · s / m2 flashes under scotopic, rod-mediated conditions 
(dashed line) and 2.5 cd · s / m2 flashes under photopic, cone-mediated conditions (solid line) 
(P15, n=4; P30, n=6; P60, n=5; P90, n=5; P120, n=5).  
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Fig. 5 
 
Fig. 5. P351Δ12 hAipl1 mice show impaired visual function. Mean threshold spatial 
frequencies (cyc/deg) of WT (n=5) and P351Δ12 hAipl1 (n=2) mice, obtained using OptoMotry, 
a virtual optokinetic stimuli apparatus (CerebralMechanics, Inc.) at (A) postnatal day 30 (P30), 
and (B) postnatal day 60 (P60). Multiple measurements were obtained across the indicated 
background light intensities under scotopic conditions. Bars and data points are mean ± SEM 
values. P values are indicated as follows: *P < 0.05, ** P < 0.005, *** P < 0.0005. 
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Fig. 6 
 
Fig. 6. Cone degeneration and cone outer segment shortening in mice with P351∆12 hAipl1 
mutation. Immunocytochemistry using indicated antibodies on retinal sections from WT hAipl1 
and P351∆12 hAipl1 mice. (A) Propidium iodide (red) was used as a marker of cell death, 
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showing photoreceptor cell death along cone nuclei stained with red/green (R/G) opsin (green) in 
retinal sections from postnatal day 17 (P17) mutant P351∆12 hAipl1 (bottom two rows) but not 
WT hAipl1 (top row) mice. (B) Rod and cone outer segments are localized with guanylate 
cyclase (GCE, green) with specific localization of cone outer segments (white arrowheads) using 
the cone arrestin antibody (cArr, red) in postnatal day 35 (P35) WT hAipl1 (top row) and 
P351∆12 hAipl1 mutant mice (bottom two rows) retinal sections. Cell nuclei are stained with 
DAPI (4’,6-diamidino-2-phenylindole, blue). COS: cone outer segment, CIS: cone inner 
segment, ONL: outer nuclear layer. Scale bar, 20 μm.  
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Fig. 7 
 
Fig. 7. P351∆12 hAipl1 mutant mice show decreased cone phosphodiesterase 6. (A) 
Immunostaining of retinal sections from P15 (top two rows) and P35 (bottom two rows) WT 
hAipl1 and P351∆12 hAipl1 mice with antibody for cone phosphodiesterase α’ subunit 
(cPDE6α’, green), co-stained with cone marker, peanut agglutinin (PNA, red). Cell nuclei are 
stained with DAPI (4’,6-diamidino-2-phenylindole, blue). Scale bar, 20 µm. COS, cone outer 
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segment; CIS, cone inner segment; ONL, outer nuclear layer. (B) Immunoblots of retinal lysates 
from P35 WT hAipl1 and P351∆12 hAipl1 mice probed with the indicated antibodies against 
cone photoreceptor proteins, cone PDE α’ and cone transducin α; and rod proteins, rod 
transducin α. Guanylyl cyclase (GC-E) is present in both cones and rods.  
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Fig. 8 
 
Fig. 8. Double transgenic mice expressing WT and P351Δ12 hAIPL1 show defects in cone-
mediated vision. P351Δ12 hAipl1 mice were crossed with WT hAipl1 mice to generate offspring 
which are potentially double transgenic positive. (A) Co-expression of WT and mutant P351Δ12 
hAIPL1 was evaluated by extensively running a 9% polyacrylamide SDS-PAGE resolving gel of 
16 cm height. Controls (Control: Flag WT and Flag Mut lanes), are run on the same gel to show 
the expected size differences. (B) ERG responses from the corresponding individual mice shown 
in the immunoblot. Photopic and scotopic responses from a mouse expressing Flag WT hAIPL1 
(Flag WT lane in immunoblot; black ERG waveforms), and two independent mice co-expressing 
Flag-WT and Flag-P351Δ12 hAIPL1 (2xFlag Tg 1, 2 in immunoblot; blue and red ERG 
waveforms).
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Fig. 9 
 
Fig. 9. WT hAipl1 gene replacement into mutant P351Δ12 hAipl1 mice rescued cone- but 
not rod-mediated ERG responses. AAV-mediated gene delivery using scAAV8-hRK-hAipl1 
viral vector, which introduced non-tagged WT hAipl1 into mutant P351Δ12 hAipl1 mice 
administered either at P10 or P15. Treated eyes showed improved (A) cone-mediated ERG 
responses, but not (B) rod-mediated ERG responses, when compared directly to its untreated eye. 
Measurements shown were obtained at P30 with 2.5 cd · s / m2 flashes with 30 cd/m2 rod-
desensitizing white background light for photopic ERG responses, and 2.5x10-2 cd · s / m2 flashes 
for scotopic ERG responses. Bars and data points are mean ± SEM values. P values are indicated 
as follows: *P < 0.05, ** P < 0.005. 
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Fig. 10 
 
Fig. 10. Treated P351Δ12 hAipl1 mice showed cone-mediated visual function. Threshold 
spatial frequencies (cyc/deg) as measured using OptoMotry, from mutant P351Δ12 hAipl1 mice 
that received AAV-mediated gene delivery of WT hAipl1 in one eye (treated) whereas the 
opposite eye remained untreated (n=4). Data points are individual threshold spatial frequency 
values, with connecting lines indicating the untreated and treated eye from the same mouse. Bars 
show mean ± SEM values (cyc/deg) of untreated and treated groups respectively, which were 
significantly different (*P < 0.05).
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Fig. 11 
 
Fig. 11. Gene introduction through AAV-mediated gene delivery shows drastically higher 
expression of WT hAipl1 than in double transgenic animals. To differentiate flag-tagged WT, 
flag-tagged mutant P351Δ12 hAIPL1, and non-tagged WT hAIPL1, we extensively ran a 9% 
polyacrylamide SDS-PAGE resolving gel of 16 cm height. Controls are run on the same gel to 
show the expected size differences. Flag-tagged WT hAIPL1 (Control: Flag WT lane), flag-
tagged P351Δ12 hAIPL1 (Control: Flag Mut lane), and non-tagged WT hAIPL1 (Control: No 
tag WT lane), show slight band shifts from highest to lowest in immunoblots, respectively. The 
control non-tagged WT hAIPL1 lane is from retinal lysate of pNrl-hAipl1 transgenic mice 
(Kirschman et al., 2010). Double transgenic animals were generated by crossing Flag-WT hAipl1 
mice with Flag-P351Δ12 hAipl1 mice, and retinal lysate from three separate animals are shown 
(2xFlag Tg lanes). Flag-P351Δ12 hAipl1 mice were administered AAV-mediated gene delivery 
of non-tagged WT hAipl1, using a scAAV8-Y733F-hAipl1 viral vector (Ku et al., 2011), and 
retinal lysate from three separate animals are shown (AAV-treated 1, 2, 3 lanes). Retinal lysate 
from double transgenic mice were age-matched to AAV-treated mice aged P130, and equal 
protein (150 µg) was loaded for all lanes.   
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Supplementary Fig. 1 
 
Supplementary Fig. 1. Cone outer segments are of relatively normal length at early ages in 
P351Δ12 hAipl1 mice. Immunostaining of retinal sections from P15 WT hAipl1 and P351Δ12 
hAipl1 mice with red/green opsin (green) and peanut agglutinin (PNA, red) showing cone outer 
segments. Cell nuclei are stained with DAPI (4’,6-diamidino-2-phenylindole, blue). Scale bar, 20 
µm. COS, cone outer segment; CIS, cone inner segment; ONL, outer nuclear layer.  
111 
 
Supplementary Fig. 2 
 
Supplementary Fig. 2. Mice positive for P351Δ12 hAipl1 transgene in a mAipl1+/- 
background do not show visual dysfunction. (A) Photopic, cone-mediated, and (B) scotopic, 
rod-mediated ERG responses of mutant P351Δ12 hAipl1 in a mAipl1+/- background (P351Δ12 
hAIPL1+ mAIPL1(+/-), middle column) mice are similar to control transgene negative mAipl1+/- 
mice (mAIPL1(+/-), left column), in contrast to the absent photopic response and decreased 
scotopic responses from mutant P351Δ12 hAipl1 in a mAipl1-/- background (P351Δ12 hAIPL1+ 
mAIPL1(-/-), right column) mice, even at older ages tested (P170 shown). Photopic and scotopic 
measurements are taken with the indicated log intensity (cd · s / m2) flashes. 
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Chapter 4 
 
General Discussion, Conclusion, and Future Work 
 
Study 1: Gene therapy for Aipl1-null mice, a model of severe Leber congenital amaurosis  
Recent advancements in AAV viral vectors were developed to treat retinal degeneration 
more rapid and severe than that seen with Rpe65-LCA. Developments in self-complementary 
AAV and viral capsid mutations demonstrated faster onset and greater transduction efficiency 
with fluorescent reporters (Natkunarajah et al., 2008; Zhong et al., 2008b; Petersen-Jones et al., 
2009; Petrs-Silva et al., 2009; Kong et al., 2010; Petrs-Silva et al., 2011). We wanted to examine 
whether these improvements translate into functional benefits. In Aipl1-null mice, the most 
severe mouse model of retinal degeneration, we evaluated whether the combined self-
complementary Y733F capsid mutant AAV2/8 (referred to as scAAV) viral vector, would 
enhance rescue over single-stranded AAV2/8 (referred to as ssAAV), the most efficient vector 
for photoreceptor targeting at that time. We observed clear functional benefits of using scAAV 
over ssAAV, particularly when treatment was administered later in disease progression at 
postnatal day 10 (P10) when photoreceptor cell death initiates in Aipl1-null mice. Early 
intervention at P2 also provided significantly greater ERG levels and morphology in scAAV-
treated as compared to ssAAV-treated, although the difference was not to the same degree as that 
observed following P10 treatment (Ku et al., 2011).  
Since our studies, AAV8-Y733F capsid mutant has been used to successfully rescue 
vision in other photoreceptor gene defects, Gucy2e (Boye, S.L. et al., 2011), Pde6brd10 (Pang et 
al., 2011), and Pde6anmf363 (Wert et al., 2012). Rescue studies of Gucy2e-null mice 
demonstrated functional benefits in cone- and rod-mediated ERG responses with AAV8-Y733F 
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over AAV5 viral vector (Boye, S.L. et al., 2011). However, it is unpredictable whether this effect 
would still hold up in a comparison with AAV8, since AAV8 was previously shown to be 
superior to AAV5 in rapid photoreceptor transduction (Allocca et al., 2007; Lebherz et al., 2008; 
Sun et al., 2010). The comparison between ssAAV8 and ssAAV8-Y733F would have been an 
important comparison since our studies had used a combined self-complementary Y733F capsid 
mutant viral vector, a development that cannot always be taken advantage of with the size 
limitation of scAAV. To our knowledge, no other AAV-mediated gene rescue studies for 
inherited retinal degeneration have compared the rescue efficacy achieved between viral vectors.  
Aipl1-null mice offer a unique model to test the functional utility of future developments 
in viral vector efficiency as new advancements emerge, such as viral particles with multiple 
surface capsid mutations (Petrs-Silva et al., 2011; Ryals et al., 2011). Lastly, successful rescue of 
Aipl1-null mice demonstrated independently by multiple groups (Tan et al., 2009; Sun et al., 
2010; Ku et al., 2011) provides proof-of-concept that even the most severe of retinal 
degenerations can be rescued if AAV-mediated gene replacement is provided prior to significant 
photoreceptor cell loss.   
 
Study 2: P351Δ12 Aipl1 mutation: a model of cone-rod dystrophy 
 While Aipl1 is mainly linked to LCA, Aipl1-CORD and -RP patients may more greatly 
benefit from AAV-mediated gene replacement since disease progression is prolonged in CORD 
and RP as compared to LCA. The P351Δ12 hAipl1 mutation has been associated with CORD and 
RP in two probands. We were interested in this mutation not for the sole purpose of pinpointing 
one Aipl1 mutation to target with gene therapy, as this would make up a minority of Aipl1 
patients even if found in additional cases. Instead, the P351Δ12 mutation brings up additional 
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questions, which we sought to answer by creating a transgenic mouse model expressing the 
mutant P351Δ12 hAIPL1 protein.  
Apart from the W278X truncation mutation shown to translate an unstable protein, it is 
unclear why some Aipl1 mutations cause LCA compared to other mutations causing less severe 
IRDs. While Aipl1-null mice phenocopies severe LCA and Aipl1-hypomorph mice phenocopies 
a very slowly progressing RP, there is no Aipl1 model that phenocopies CORD. With the 
association of P351Δ12 hAipl1 to CORD, this transgenic mouse model may offer some insight to 
the role of hAipl1 in cones. The P351Δ12 hAipl1 is also associated with autosomal dominant 
disease which we thought a priori would preclude it from benefitting from AAV-mediated gene 
replacement therapy. However, the autosomal dominant inheritance pattern brought up 
interesting possibilities in examining abnormal and normal interacting protein partners of hAipl1, 
since it signifies a possible dominant negative effect of the mutation. 
We investigated the phenotype of mice expressing mutant P351Δ12 hAIPL1 and 
observed visual defects mimicking cone-rod dystrophy (CORD). This is in agreement with a 
reported P351Δ12 hAipl1 patient, although a second patient had a discordant diagnosis of 
juvenile RP (Sohocki et al., 2000b). In our transgenic P351Δ12 hAipl1-CORD model, we 
attribute the observed cone defects to decreased cone phosphodiesterase 6 (cPDE6). In addition 
to dramatic cone defects, we observed early defects at postnatal day 15 in rod-mediated ERG 
responses and subsequent rod cell loss, which we attribute to decreased rod transducin. A 
reduction in rod transducin would produce subsequent defects in signal transduction, which is 
reflected in our observations of reduced sensitivity in rod-mediated vision in P351Δ12 hAipl1 
mice.  
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P351Δ12 hAipl1 was specifically linked with autosomal dominant retinal degeneration, 
which has not been otherwise observed with Aipl1 defects. We confirmed autosomal dominant 
disease associated with the P351Δ12 mutation through double transgenic mice co-expressing WT 
and mutant P351Δ12 hAIPL1, which continued to show cone and rod visual defects. However, 
drastic overexpression of WT hAIPL1 with AAV-mediated gene delivery into P351Δ12 hAipl1 
mice rescued cone, although not rod, defects. Further work is needed to examine the mechanism 
of dominant dysfunction with P351Δ12 hAIPL1, which may differ in cones and rods as 
suggested by these rescue studies.  
This also implicates that the normal role of Aipl1 differs in cones and rods, a question 
that is currently being investigated in a ‘cone-only’ retina lacking mAipl1 (Nrl-/-/Aipl1-/- double 
knockout mice) (Kolandaivelu et al., manuscript in preparation). Nrl (neural retina-specific 
leucine zipper) is an important transcription factor specifying rod photoreceptor differentiation, 
therefore, all photoreceptors develop into cone-like cells in Nrl-/- mice. In Nrl-/-/Aipl1-/- mice, 
the lack of mAipl1 in cones leads to de-stabilized cPDE6 observed in pulse-chase experiments 
and a subsequent dramatic decrease in cPDE6 levels (Kolandaivelu et al., manuscript in 
preparation). These studies affirm the role of Aipl1 in cPDE6, but does not confirm nor exclude a 
dominant negative effect of the P351Δ12 hAIPL1 mutation on cPDE6. However, P351Δ12 
hAIPL1 dysfunction in cones could potentially be examined through a comparison of interacting 
partners between Flag-WT hAIPL1 and Flag-P351Δ12 hAIPL1 in an Nrl-/-/Aipl1-/- background 
in future studies. 
In regards to the rod dysfunction observed in P351Δ12 hAipl1 mice, decreased rod 
transducin may stem from an active dominant negative effect of mutant P351Δ12 hAIPL1 on this 
essential phototransduction protein. An alternative explanation is that mutant P351Δ12 hAIPL1 
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shows lower stability or activity than WT hAIPL1, resulting in subpar functioning of AIPL1. 
This theoretical possibility would also have to assume functional differences between human and 
mouse AIPL1, since mAipl1-hypomorphic mice expressing 20-25% of normal mAIPL1 levels do 
not show defects in rod transducin (Liu et al., 2004).   
A last question that remains to be examined is the role of the C-terminal primate-specific 
region in human AIPL1. In addition to ensuring that mutant P351Δ12 hAIPL1 effects were not 
due to mCrx promoter insufficiencies, another reason we generated a control WT hAipl1 
transgene line was to examine interacting partners of human AIPL1 using the N-terminal flag-
epitope tag. Initial attempts at flag co-immunoprecipitation were unsuccessful as background 
binding to flag agarose beads was high, however, use of flag magnetic beads may yield cleaner 
results. Although we were unable to directly answer this question in our current studies, our 
findings clearly indicate that mutations in this region lead to visual dysfunction and 
degeneration. Altogether, we conclude that our transgenic P351Δ12 hAipl1 mouse offers a novel 
model for Aipl1-CORD, which can be further used to evaluate the mechanism of dominant 
dysfunction, and that our WT hAipl1 line can be further used to examine the normal role of 
hAipl1 in cones.  
 
Summary: 
 Our work demonstrates that visual dysfunction associated with Aipl1 defects can be 
significantly improved with AAV-mediated gene therapy, in both Aipl1-null mice modeling 
Aipl1-LCA and transgenic P351Δ12 hAipl1 mice modeling Aipl1-CORD. Although our work 
confirms that dominant disease is likely with a P351Δ12 mutation in a heterozygous state, 
overexpression of WT hAIPL1 with AAV-mediated therapy can rescue cone defects, and if 
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directly targeted to the macula, AAV treatment would still drastically help maintain visual 
function in patients. These studies indicate Aipl1 as a potential candidate for future AAV gene 
therapy clinical trials, provided that early intervention is administered to a patient with a slower 
progressing disease. Additionally, Aipl1 is small enough to be packaged within a self-
complementary AAV vector with extremely rapid and efficient transduction, which provides an 
advantage of targeting Aipl1 over other genes with a similar predicted rapid progression of 
retinal degeneration.  
118 
 
References 
1. Acland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, 
J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K. et al. (2005) 
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene 
transfer to the retina in a canine model of childhood blindness. Mol Ther, 12, 1072-1082. 
2. Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., 
Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M. et al. (2001) Gene therapy 
restores vision in a canine model of childhood blindness. Nat Genet, 28, 92-95. 
3. Aguirre, G. K., Komaromy, A. M., Cideciyan, A. V., Brainard, D. H., Aleman, T. S., 
Roman, A. J., Avants, B. B., Gee, J. C., Korczykowski, M., Hauswirth, W. W. et al. 
(2007) Canine and human visual cortex intact and responsive despite early retinal 
blindness from RPE65 mutation. PLoS Med, 4, e230. 
4. Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H. and Kay, M. A. (2006) The 
37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 
3, and 9. J Virol, 80, 9831-9836. 
5. Akimoto, M., Cheng, H., Zhu, D., Brzezinski, J. A., Khanna, R., Filippova, E., Oh, E. C., 
Jing, Y., Linares, J. L., Brooks, M. et al. (2006) Targeting of GFP to newborn rods by Nrl 
promoter and temporal expression profiling of flow-sorted photoreceptors. Proc Natl 
Acad Sci U S A, 103, 3890-3895. 
6. Ali, R. R., Reichel, M. B., De Alwis, M., Kanuga, N., Kinnon, C., Levinsky, R. J., Hunt, 
D. M., Bhattacharya, S. S. and Thrasher, A. J. (1998) Adeno-associated virus gene 
transfer to mouse retina. Hum Gene Ther, 9, 81-86. 
7. Ali, R. R., Reichel, M. B., Hunt, D. M. and Bhattacharya, S. S. (1997) Gene therapy for 
inherited retinal degeneration. Br J Ophthalmol, 81, 795-801. 
8. Ali, R. R., Reichel, M. B., Thrasher, A. J., Levinsky, R. J., Kinnon, C., Kanuga, N., Hunt, 
D. M. and Bhattacharya, S. S. (1996) Gene transfer into the mouse retina mediated by an 
adeno-associated viral vector. Hum Mol Genet, 5, 591-594. 
9. Allocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. 
R., Maguire, A., Rex, T. S., Di Vicino, U. et al. (2008) Serotype-dependent packaging of 
large genes in adeno-associated viral vectors results in effective gene delivery in mice. J 
Clin Invest, 118, 1955-1964. 
10. Allocca, M., Mussolino, C., Garcia-Hoyos, M., Sanges, D., Iodice, C., Petrillo, M., 
Vandenberghe, L. H., Wilson, J. M., Marigo, V., Surace, E. M. et al. (2007) Novel 
adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol, 81, 
11372-11380. 
11. Atchison, R. W., Casto, B. C. and Hammon, W. M. (1965) ADENOVIRUS-
ASSOCIATED DEFECTIVE VIRUS PARTICLES. Science, 149, 754-756. 
12. Bainbridge, J. W., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., 
Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N. et al. (2008) Effect of gene 
therapy on visual function in Leber's congenital amaurosis. N Engl J Med, 358, 2231-
2239. 
13. Beltran, W. A. (2009) The use of canine models of inherited retinal degeneration to test 
novel therapeutic approaches. Vet Ophthalmol, 12, 192-204. 
119 
 
14. Bennett, J., Duan, D., Engelhardt, J. F. and Maguire, A. M. (1997) Real-time, 
noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction. 
Invest Ophthalmol Vis Sci, 38, 2857-2863. 
15. Bennett, J., Wilson, J., Sun, D., Forbes, B. and Maguire, A. (1994) Adenovirus vector-
mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci, 35, 
2535-2542. 
16. Bennicelli, J., Wright, J. F., Komaromy, A., Jacobs, J. B., Hauck, B., Zelenaia, O., 
Mingozzi, F., Hui, D., Chung, D., Rex, T. S. et al. (2008) Reversal of blindness in animal 
models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. 
Mol Ther, 16, 458-465. 
17. Berger, W., Kloeckener-Gruissem, B. and Neidhardt, J. (2010) The molecular basis of 
human retinal and vitreoretinal diseases. Prog Retin Eye Res, 29, 335-375. 
18. Besch, D., Jagle, H., Scholl, H. P., Seeliger, M. W. and Zrenner, E. (2003) Inherited 
multifocal RPE-diseases: mechanisms for local dysfunction in global retinoid cycle gene 
defects. Vision Res, 43, 3095-3108. 
19. Boye, S. E. (2012) Transduction of the Outer Retina [oral presentation]. In: Association 
for Research in Vision and Ophthalmology (ARVO) annual meeting; 2012 May 6-9. Ft. 
Lauderdale, FL. 
20. Boye, S. L., Conlon, T., Erger, K., Ryals, R., Neeley, A., Cossette, T., Pang, J., Dyka, F. 
M., Hauswirth, W. W. and Boye, S. E. (2011) Long-term preservation of cone 
photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-
1 knockout (GC1KO) mouse. Invest Ophthalmol Vis Sci, 52, 7098-7108. 
21. Burova, E. and Ioffe, E. (2005) Chromatographic purification of recombinant adenoviral 
and adeno-associated viral vectors: methods and implications. Gene Ther, 12 Suppl 1, 
S5-17. 
22. Chang, L. S., Shi, Y. and Shenk, T. (1989) Adeno-associated virus P5 promoter contains 
an adenovirus E1A-inducible element and a binding site for the major late transcription 
factor. J Virol, 63, 3479-3488. 
23. Chen, Y., Moiseyev, G., Takahashi, Y. and Ma, J. X. (2006) RPE65 gene delivery 
restores isomerohydrolase activity and prevents early cone loss in Rpe65-/- mice. Invest 
Ophthalmol Vis Sci, 47, 1177-1184. 
24. Cideciyan, A. V. (2010) Leber congenital amaurosis due to RPE65 mutations and its 
treatment with gene therapy. Prog Retin Eye Res, 29, 398-427. 
25. Cideciyan, A. V., Aleman, T. S., Boye, S. L., Schwartz, S. B., Kaushal, S., Roman, A. J., 
Pang, J. J., Sumaroka, A., Windsor, E. A., Wilson, J. M. et al. (2008) Human gene 
therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with 
slow rod kinetics. Proc Natl Acad Sci U S A, 105, 15112-15117. 
26. Cideciyan, A. V., Aleman, T. S., Jacobson, S. G., Khanna, H., Sumaroka, A., Aguirre, G. 
K., Schwartz, S. B., Windsor, E. A., He, S., Chang, B. et al. (2007) Centrosomal-ciliary 
gene CEP290/NPHP6 mutations result in blindness with unexpected sparing of 
photoreceptors and visual brain: implications for therapy of Leber congenital amaurosis. 
Hum Mutat, 28, 1074-1083. 
27. Cideciyan, A. V., Hauswirth, W. W., Aleman, T. S., Kaushal, S., Schwartz, S. B., Boye, 
S. L., Windsor, E. A., Conlon, T. J., Sumaroka, A., Pang, J. J. et al. (2009) Human 
RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual 
improvements and safety at 1 year. Hum Gene Ther, 20, 999-1004. 
120 
 
28. Clark, K. R., Liu, X., McGrath, J. P. and Johnson, P. R. (1999) Highly purified 
recombinant adeno-associated virus vectors are biologically active and free of detectable 
helper and wild-type viruses. Hum Gene Ther, 10, 1031-1039. 
29. Clark, K. R. and Penaud-Budloo, M. (2011) Evaluation of the fate of rAAV genomes 
following in vivo administration. Methods Mol Biol, 807, 239-258. 
30. Colella, P., Cotugno, G. and Auricchio, A. (2009) Ocular gene therapy: current progress 
and future prospects. Trends Mol Med, 15, 23-31. 
31. Collaco, R. F., Cao, X. and Trempe, J. P. (1999) A helper virus-free packaging system for 
recombinant adeno-associated virus vectors. Gene, 238, 397-405. 
32. Daiger, S. P., Bowne, S. J. and Sullivan, L. S. (2007) Perspective on genes and mutations 
causing retinitis pigmentosa. Arch Ophthalmol, 125, 151-158. 
33. Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V. 
and Flannery, J. G. (2009) Inner limiting membrane barriers to AAV-mediated retinal 
transduction from the vitreous. Mol Ther, 17, 2096-2102. 
34. de Backer, M. W., Garner, K. M., Luijendijk, M. C. and Adan, R. A. (2011) Recombinant 
adeno-associated viral vectors. Methods Mol Biol, 789, 357-376. 
35. Dejneka, N. S., Surace, E. M., Aleman, T. S., Cideciyan, A. V., Lyubarsky, A., 
Savchenko, A., Redmond, T. M., Tang, W., Wei, Z., Rex, T. S. et al. (2004) In utero gene 
therapy rescues vision in a murine model of congenital blindness. Mol Ther, 9, 182-188. 
36. Dharmaraj, S., Leroy, B. P., Sohocki, M. M., Koenekoop, R. K., Perrault, I., Anwar, K., 
Khaliq, S., Devi, R. S., Birch, D. G., De Pool, E. et al. (2004) The phenotype of Leber 
congenital amaurosis in patients with AIPL1 mutations. Arch Ophthalmol, 122, 1029-
1037. 
37. Dong, B., Nakai, H. and Xiao, W. (2010) Characterization of genome integrity for 
oversized recombinant AAV vector. Mol Ther, 18, 87-92. 
38. Douglas, R. M., Alam, N. M., Silver, B. D., McGill, T. J., Tschetter, W. W. and Prusky, 
G. T. (2005) Independent visual threshold measurements in the two eyes of freely 
moving rats and mice using a virtual-reality optokinetic system. Vis Neurosci, 22, 677-
684. 
39. Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J. and 
Engelhardt, J. F. (1998) Circular intermediates of recombinant adeno-associated virus 
have defined structural characteristics responsible for long-term episomal persistence in 
muscle tissue. J Virol, 72, 8568-8577. 
40. Dyer, M. A., Donovan, S. L., Zhang, J., Gray, J., Ortiz, A., Tenney, R., Kong, J., 
Allikmets, R. and Sohocki, M. M. (2004) Retinal degeneration in Aipl1-deficient mice: a 
new genetic model of Leber congenital amaurosis. Brain Res Mol Brain Res, 132, 208-
220. 
41. Fan, P. D. and Dong, J. Y. (1997) Replication of rep-cap genes is essential for the high-
efficiency production of recombinant AAV. Hum Gene Ther, 8, 87-98. 
42. Feng, W., Yasumura, D., Matthes, M. T., LaVail, M. M. and Vollrath, D. (2002) Mertk 
triggers uptake of photoreceptor outer segments during phagocytosis by cultured retinal 
pigment epithelial cells. J Biol Chem, 277, 17016-17022. 
43. Ferrari, F. K., Samulski, T., Shenk, T. and Samulski, R. J. (1996) Second-strand synthesis 
is a rate-limiting step for efficient transduction by recombinant adeno-associated virus 
vectors. J Virol, 70, 3227-3234. 
121 
 
44. Ferrari, F. K., Xiao, X., McCarty, D. and Samulski, R. J. (1997) New developments in 
the generation of Ad-free, high-titer rAAV gene therapy vectors. Nat Med, 3, 1295-1297. 
45. Flannery, J. G., Zolotukhin, S., Vaquero, M. I., LaVail, M. M., Muzyczka, N. and 
Hauswirth, W. W. (1997) Efficient photoreceptor-targeted gene expression in vivo by 
recombinant adeno-associated virus. Proc Natl Acad Sci U S A, 94, 6916-6921. 
46. Foxman, S. G., Heckenlively, J. R., Bateman, J. B. and Wirtschafter, J. D. (1985) 
Classification of congenital and early onset retinitis pigmentosa. Arch Ophthalmol, 103, 
1502-1506. 
47. Fulton, A. B., Hansen, R. M. and Mayer, D. L. (1996) Vision in Leber congenital 
amaurosis. Arch Ophthalmol, 114, 698-703. 
48. Fulton, A. B. and Rushton, W. A. (1978) The human rod ERG: correlation with 
psychophysical responses in light and dark adaptation. Vision Res, 18, 793-800. 
49. Furukawa, A., Koike, C., Lippincott, P., Cepko, C. L. and Furukawa, T. (2002) The 
mouse Crx 5'-upstream transgene sequence directs cell-specific and developmentally 
regulated expression in retinal photoreceptor cells. J Neurosci, 22, 1640-1647. 
50. Galvin, J. A., Fishman, G. A., Stone, E. M. and Koenekoop, R. K. (2005) Evaluation of 
genotype-phenotype associations in leber congenital amaurosis. Retina, 25, 919-929. 
51. Gao, G. P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J. and Wilson, J. M. (2002) 
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. 
Proc Natl Acad Sci U S A, 99, 11854-11859. 
52. Giove, T. J., Sena-Esteves, M. and Eldred, W. D. (2010) Transduction of the inner mouse 
retina using AAVrh8 and AAVrh10 via intravitreal injection. Exp Eye Res, 91, 652-659. 
53. Goncalves, M. A. (2005) Adeno-associated virus: from defective virus to effective 
vector. Virol J, 2, 43. 
54. Gouras, P., Kong, J. and Tsang, S. H. (2002) Retinal degeneration and RPE 
transplantation in Rpe65(-/-) mice. Invest Ophthalmol Vis Sci, 43, 3307-3311. 
55. Grant, C. A., Ponnazhagan, S., Wang, X. S., Srivastava, A. and Li, T. (1997) Evaluation 
of recombinant adeno-associated virus as a gene transfer vector for the retina. Curr Eye 
Res, 16, 949-956. 
56. Grieger, J. C. and Samulski, R. J. (2005) Packaging capacity of adeno-associated virus 
serotypes: impact of larger genomes on infectivity and postentry steps. J Virol, 79, 9933-
9944. 
57. Grimm, D., Kern, A., Rittner, K. and Kleinschmidt, J. A. (1998) Novel tools for 
production and purification of recombinant adenoassociated virus vectors. Hum Gene 
Ther, 9, 2745-2760. 
58. Hanein, S., Perrault, I., Gerber, S., Tanguy, G., Barbet, F., Ducroq, D., Calvas, P., 
Dollfus, H., Hamel, C., Lopponen, T. et al. (2004) Leber congenital amaurosis: 
comprehensive survey of the genetic heterogeneity, refinement of the clinical definition, 
and genotype-phenotype correlations as a strategy for molecular diagnosis. Hum Mutat, 
23, 306-317. 
59. Harvey, A. R., Kamphuis, W., Eggers, R., Symons, N. A., Blits, B., Niclou, S., Boer, G. 
J. and Verhaagen, J. (2002) Intravitreal injection of adeno-associated viral vectors results 
in the transduction of different types of retinal neurons in neonatal and adult rats: a 
comparison with lentiviral vectors. Mol Cell Neurosci, 21, 141-157. 
60. Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, 
L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J. et al. (2008) Treatment of leber 
122 
 
congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-
associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther, 19, 
979-990. 
61. Hendrickson, A., Bumsted-O'Brien, K., Natoli, R., Ramamurthy, V., Possin, D. and 
Provis, J. (2008) Rod photoreceptor differentiation in fetal and infant human retina. Exp 
Eye Res, 87, 415-426. 
62. Hermonat, P. L. and Muzyczka, N. (1984) Use of adeno-associated virus as a mammalian 
DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture 
cells. Proc Natl Acad Sci U S A, 81, 6466-6470. 
63. Hernandez, M., Pearce-Kelling, S. E., Rodriguez, F. D., Aguirre, G. D. and Vecino, E. 
(2010) Altered expression of retinal molecular markers in the canine RPE65 model of 
Leber congenital amaurosis. Invest Ophthalmol Vis Sci, 51, 6793-6802. 
64. Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., 
Windsor, E. A., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H. et al. (2005) 
Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for 
human gene therapy success. Proc Natl Acad Sci U S A, 102, 6177-6182. 
65. Jacobson, S. G., Boye, S. L., Aleman, T. S., Conlon, T. J., Zeiss, C. J., Roman, A. J., 
Cideciyan, A. V., Schwartz, S. B., Komaromy, A. M., Doobrajh, M. et al. (2006) Safety 
in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in 
Leber congenital amaurosis. Hum Gene Ther, 17, 845-858. 
66. Jacobson, S. G., Cideciyan, A. V., Aleman, T. S., Sumaroka, A., Roman, A. J., Swider, 
M., Schwartz, S. B., Banin, E. and Stone, E. M. (2011) Human retinal disease from 
AIPL1 gene mutations: foveal cone loss with minimal macular photoreceptors and rod 
function remaining. Invest Ophthalmol Vis Sci, 52, 70-79. 
67. Jacobson, S. G., Cideciyan, A. V., Aleman, T. S., Sumaroka, A., Schwartz, S. B., Roman, 
A. J. and Stone, E. M. (2007) Leber congenital amaurosis caused by an RPGRIP1 
mutation shows treatment potential. Ophthalmology, 114, 895-898. 
68. Jacobson, S. G., Cideciyan, A. V., Ratnakaram, R., Heon, E., Schwartz, S. B., Roman, A. 
J., Peden, M. C., Aleman, T. S., Boye, S. L., Sumaroka, A. et al. (2012) Gene therapy for 
leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 
children and adults followed up to 3 years. Arch Ophthalmol, 130, 9-24. 
69. Janik, J. E., Huston, M. M., Cho, K. and Rose, J. A. (1989) Efficient synthesis of adeno-
associated virus structural proteins requires both adenovirus DNA binding protein and 
VA I RNA. Virology, 168, 320-329. 
70. Jay, F. T., Laughlin, C. A. and Carter, B. J. (1981) Eukaryotic translational control: 
adeno-associated virus protein synthesis is affected by a mutation in the adenovirus 
DNA-binding protein. Proc Natl Acad Sci U S A, 78, 2927-2931. 
71. Jomary, C., Piper, T. A., Dickson, G., Couture, L. A., Smith, A. E., Neal, M. J. and Jones, 
S. E. (1994) Adenovirus-mediated gene transfer to murine retinal cells in vitro and in 
vivo. FEBS Lett, 347, 117-122. 
72. Jomary, C., Vincent, K. A., Grist, J., Neal, M. J. and Jones, S. E. (1997) Rescue of 
photoreceptor function by AAV-mediated gene transfer in a mouse model of inherited 
retinal degeneration. Gene Ther, 4, 683-690. 
73. Jooss, K., Yang, Y., Fisher, K. J. and Wilson, J. M. (1998) Transduction of dendritic cells 
by DNA viral vectors directs the immune response to transgene products in muscle fibers. 
J Virol, 72, 4212-4223. 
123 
 
74. Kautzmann, M. A., Kim, D. S., Felder-Schmittbuhl, M. P. and Swaroop, A. (2011) 
Combinatorial regulation of photoreceptor differentiation factor, neural retina leucine 
zipper gene NRL, revealed by in vivo promoter analysis. J Biol Chem, 286, 28247-28255. 
75. Kevany, B. M. and Palczewski, K. (2010) Phagocytosis of retinal rod and cone 
photoreceptors. Physiology (Bethesda), 25, 8-15. 
76. Khani, S. C., Pawlyk, B. S., Bulgakov, O. V., Kasperek, E., Young, J. E., Adamian, M., 
Sun, X., Smith, A. J., Ali, R. R. and Li, T. (2007) AAV-mediated expression targeting of 
rod and cone photoreceptors with a human rhodopsin kinase promoter. Invest Ophthalmol 
Vis Sci, 48, 3954-3961. 
77. Kirschman, L. T., Kolandaivelu, S., Frederick, J. M., Dang, L., Goldberg, A. F., Baehr, 
W. and Ramamurthy, V. (2010) The Leber congenital amaurosis protein, AIPL1, is 
needed for the viability and functioning of cone photoreceptor cells. Hum Mol Genet, 19, 
1076-1087. 
78. Koenekoop, R. K. (2004) An overview of Leber congenital amaurosis: a model to 
understand human retinal development. Surv Ophthalmol, 49, 379-398. 
79. Kolandaivelu, S., Huang, J., Hurley, J. B. and Ramamurthy, V. (2009) AIPL1, a protein 
associated with childhood blindness, interacts with alpha-subunit of rod 
phosphodiesterase (PDE6) and is essential for its proper assembly. J Biol Chem, 284, 
30853-30861. 
80. Kolesnikov, A. V., Fan, J., Crouch, R. K. and Kefalov, V. J. (2010) Age-related 
deterioration of rod vision in mice. J Neurosci, 30, 11222-11231. 
81. Kolstad, K. D., Dalkara, D., Guerin, K., Visel, M., Hoffmann, N., Schaffer, D. V. and 
Flannery, J. G. (2010) Changes in adeno-associated virus-mediated gene delivery in 
retinal degeneration. Hum Gene Ther, 21, 571-578. 
82. Kong, F., Li, W., Li, X., Zheng, Q., Dai, X., Zhou, X., Boye, S. L., Hauswirth, W. W., 
Qu, J. and Pang, J. J. (2010) Self-complementary AAV5 vector facilitates quicker 
transgene expression in photoreceptor and retinal pigment epithelial cells of normal 
mouse. Exp Eye Res, 90, 546-554. 
83. Kotin, R. M., Menninger, J. C., Ward, D. C. and Berns, K. I. (1991) Mapping and direct 
visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. 
Genomics, 10, 831-834. 
84. Ku, C. A., Chiodo, V. A., Boye, S. L., Goldberg, A. F., Li, T., Hauswirth, W. W. and 
Ramamurthy, V. (2011) Gene therapy using self-complementary Y733F capsid mutant 
AAV2/8 restores vision in a model of early onset Leber congenital amaurosis. Hum Mol 
Genet, 20, 4569-4581. 
85. Kuksa, V., Imanishi, Y., Batten, M., Palczewski, K. and Moise, A. R. (2003) Retinoid 
cycle in the vertebrate retina: experimental approaches and mechanisms of isomerization. 
Vision Res, 43, 2959-2981. 
86. Lebherz, C., Maguire, A., Tang, W., Bennett, J. and Wilson, J. M. (2008) Novel AAV 
serotypes for improved ocular gene transfer. J Gene Med, 10, 375-382. 
87. Li, J., Samulski, R. J. and Xiao, X. (1997) Role for highly regulated rep gene expression 
in adeno-associated virus vector production. J Virol, 71, 5236-5243. 
88. Li, T., Adamian, M., Roof, D. J., Berson, E. L., Dryja, T. P., Roessler, B. J. and 
Davidson, B. L. (1994) In vivo transfer of a reporter gene to the retina mediated by an 
adenoviral vector. Invest Ophthalmol Vis Sci, 35, 2543-2549. 
124 
 
89. Li, T. and Davidson, B. L. (1995) Phenotype correction in retinal pigment epithelium in 
murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer. Proc Natl 
Acad Sci U S A, 92, 7700-7704. 
90. Liu, X., Bulgakov, O. V., Wen, X. H., Woodruff, M. L., Pawlyk, B., Yang, J., Fain, G. 
L., Sandberg, M. A., Makino, C. L. and Li, T. (2004) AIPL1, the protein that is defective 
in Leber congenital amaurosis, is essential for the biosynthesis of retinal rod cGMP 
phosphodiesterase. Proc Natl Acad Sci U S A, 101, 13903-13908. 
91. Machida, S., Kondo, M., Jamison, J. A., Khan, N. W., Kononen, L. T., Sugawara, T., 
Bush, R. A. and Sieving, P. A. (2000) P23H rhodopsin transgenic rat: correlation of 
retinal function with histopathology. Invest Ophthalmol Vis Sci, 41, 3200-3209. 
92. Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., 
Mingozzi, F., Bennicelli, J. L., Ying, G. S., Rossi, S. et al. (2009) Age-dependent effects 
of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. 
Lancet, 374, 1597-1605. 
93. Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Jr., Mingozzi, F., Bennicelli, J., 
Banfi, S., Marshall, K. A., Testa, F., Surace, E. M. et al. (2008) Safety and efficacy of 
gene transfer for Leber's congenital amaurosis. N Engl J Med, 358, 2240-2248. 
94. Matsuda, T. and Cepko, C. L. (2004) Electroporation and RNA interference in the rodent 
retina in vivo and in vitro. Proc Natl Acad Sci U S A, 101, 16-22. 
95. McCarty, D. M. (2008) Self-complementary AAV vectors; advances and applications. 
Mol Ther, 16, 1648-1656. 
96. McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P. and Samulski, R. J. 
(2003) Adeno-associated virus terminal repeat (TR) mutant generates self-
complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene 
Ther, 10, 2112-2118. 
97. McCarty, D. M., Monahan, P. E. and Samulski, R. J. (2001) Self-complementary 
recombinant adeno-associated virus (scAAV) vectors promote efficient transduction 
independently of DNA synthesis. Gene Ther, 8, 1248-1254. 
98. McCoy, R. D., Davidson, B. L., Roessler, B. J., Huffnagle, G. B., Janich, S. L., Laing, T. 
J. and Simon, R. H. (1995) Pulmonary inflammation induced by incomplete or 
inactivated adenoviral particles. Hum Gene Ther, 6, 1553-1560. 
99. Miller, D. G., Petek, L. M. and Russell, D. W. (2004) Adeno-associated virus vectors 
integrate at chromosome breakage sites. Nat Genet, 36, 767-773. 
100. Monahan, P. E., Samulski, R. J., Tazelaar, J., Xiao, X., Nichols, T. C., Bellinger, D. A., 
Read, M. S. and Walsh, C. E. (1998) Direct intramuscular injection with recombinant 
AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther, 5, 
40-49. 
101. Muzyczka, N., Samulski, R. J., Hermonat, P., Srivastava, A. and Berns, K. I. (1984) The 
genetics of adeno-associated virus. Adv Exp Med Biol, 179, 151-161. 
102. Narfstrom, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. 
M., Caro, L., Lai, C. M. and Rakoczy, P. E. (2003) Functional and structural recovery of 
the retina after gene therapy in the RPE65 null mutation dog. Invest Ophthalmol Vis Sci, 
44, 1663-1672. 
103. Natkunarajah, M., Trittibach, P., McIntosh, J., Duran, Y., Barker, S. E., Smith, A. J., 
Nathwani, A. C. and Ali, R. R. (2008) Assessment of ocular transduction using single-
125 
 
stranded and self-complementary recombinant adeno-associated virus serotype 2/8. Gene 
Ther, 15, 463-467. 
104. Noble, K. G. and Carr, R. E. (1978) Leber's congenital amaurosis. A retrospective study 
of 33 cases and a histopathological study of one case. Arch Ophthalmol, 96, 818-821. 
105. Pang, J. J., Boye, S. L., Kumar, A., Dinculescu, A., Deng, W., Li, J., Li, Q., Rani, A., 
Foster, T. C., Chang, B. et al. (2008) AAV-mediated gene therapy for retinal 
degeneration in the rd10 mouse containing a recessive PDEbeta mutation. Invest 
Ophthalmol Vis Sci, 49, 4278-4283. 
106. Pang, J. J., Chang, B., Hawes, N. L., Hurd, R. E., Davisson, M. T., Li, J., Noorwez, S. 
M., Malhotra, R., McDowell, J. H., Kaushal, S. et al. (2005) Retinal degeneration 12 
(rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis 
(LCA). Mol Vis, 11, 152-162. 
107. Pang, J. J., Chang, B., Kumar, A., Nusinowitz, S., Noorwez, S. M., Li, J., Rani, A., 
Foster, T. C., Chiodo, V. A., Doyle, T. et al. (2006) Gene therapy restores vision-
dependent behavior as well as retinal structure and function in a mouse model of RPE65 
Leber congenital amaurosis. Mol Ther, 13, 565-572. 
108. Pang, J. J., Dai, X., Boye, S. E., Barone, I., Boye, S. L., Mao, S., Everhart, D., 
Dinculescu, A., Liu, L., Umino, Y. et al. (2011) Long-term retinal function and structure 
rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis 
pigmentosa. Mol Ther, 19, 234-242. 
109. Pasadhika, S., Fishman, G. A., Stone, E. M., Lindeman, M., Zelkha, R., Lopez, I., 
Koenekoop, R. K. and Shahidi, M. (2010) Differential macular morphology in patients 
with RPE65-, CEP290-, GUCY2D-, and AIPL1-related Leber congenital amaurosis. 
Invest Ophthalmol Vis Sci, 51, 2608-2614. 
110. Penaud-Budloo, M., Le Guiner, C., Nowrouzi, A., Toromanoff, A., Cherel, Y., 
Chenuaud, P., Schmidt, M., von Kalle, C., Rolling, F., Moullier, P. et al. (2008) Adeno-
associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol, 
82, 7875-7885. 
111. Pennesi, M. E., Stover, N. B., Stone, E. M., Chiang, P. W. and Weleber, R. G. (2011) 
Residual electroretinograms in young Leber congenital amaurosis patients with mutations 
of AIPL1. Invest Ophthalmol Vis Sci, 52, 8166-8173. 
112. Perrault, I., Rozet, J. M., Gerber, S., Ghazi, I., Leowski, C., Ducroq, D., Souied, E., 
Dufier, J. L., Munnich, A. and Kaplan, J. (1999) Leber congenital amaurosis. Mol Genet 
Metab, 68, 200-208. 
113. Petersen-Jones, S. M., Bartoe, J. T., Fischer, A. J., Scott, M., Boye, S. L., Chiodo, V. and 
Hauswirth, W. W. (2009) AAV retinal transduction in a large animal model species: 
comparison of a self-complementary AAV2/5 with a single-stranded AAV2/5 vector. 
Mol Vis, 15, 1835-1842. 
114. Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W. T., Pang, J. J., Min, S. H., Chiodo, V., 
Neeley, A. W., Govindasamy, L., Bennett, A. et al. (2011) Novel properties of tyrosine-
mutant AAV2 vectors in the mouse retina. Mol Ther, 19, 293-301. 
115. Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S. H., Chiodo, V., Pang, J. J., Zhong, L., 
Zolotukhin, S., Srivastava, A., Lewin, A. S. et al. (2009) High-efficiency transduction of 
the mouse retina by tyrosine-mutant AAV serotype vectors. Mol Ther, 17, 463-471. 
126 
 
116. Ramamurthy, V., Niemi, G. A., Reh, T. A. and Hurley, J. B. (2004) Leber congenital 
amaurosis linked to AIPL1: a mouse model reveals destabilization of cGMP 
phosphodiesterase. Proc Natl Acad Sci U S A, 101, 13897-13902. 
117. Ramamurthy, V., Roberts, M., van den Akker, F., Niemi, G., Reh, T. A. and Hurley, J. B. 
(2003) AIPL1, a protein implicated in Leber's congenital amaurosis, interacts with and 
aids in processing of farnesylated proteins. Proc Natl Acad Sci U S A, 100, 12630-12635. 
118. Redmond, T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J. X., 
Crouch, R. K. and Pfeifer, K. (1998) Rpe65 is necessary for production of 11-cis-vitamin 
A in the retinal visual cycle. Nat Genet, 20, 344-351. 
119. Reichel, M. B., Ali, R. R., Thrasher, A. J., Hunt, D. M., Bhattacharya, S. S. and Baker, D. 
(1998) Immune responses limit adenovirally mediated gene expression in the adult mouse 
eye. Gene Ther, 5, 1038-1046. 
120. Richardson, W. D. and Westphal, H. (1984) Requirement for either early region 1a or 
early region 1b adenovirus gene products in the helper effect for adeno-associated virus. J 
Virol, 51, 404-410. 
121. Roman, A. J., Cideciyan, A. V., Aleman, T. S. and Jacobson, S. G. (2007) Full-field 
stimulus testing (FST) to quantify visual perception in severely blind candidates for 
treatment trials. Physiol Meas, 28, N51-56. 
122. Ryals, R. C., Boye, S. L., Dinculescu, A., Hauswirth, W. W. and Boye, S. E. (2011) 
Quantifying transduction efficiencies of unmodified and tyrosine capsid mutant AAV 
vectors in vitro using two ocular cell lines. Mol Vis, 17, 1090-1102. 
123. Samulski, R. J., Berns, K. I., Tan, M. and Muzyczka, N. (1982) Cloning of adeno-
associated virus into pBR322: rescue of intact virus from the recombinant plasmid in 
human cells. Proc Natl Acad Sci U S A, 79, 2077-2081. 
124. Samulski, R. J., Chang, L. S. and Shenk, T. (1989) Helper-free stocks of recombinant 
adeno-associated viruses: normal integration does not require viral gene expression. J 
Virol, 63, 3822-3828. 
125. Samulski, R. J. and Shenk, T. (1988) Adenovirus E1B 55-Mr polypeptide facilitates 
timely cytoplasmic accumulation of adeno-associated virus mRNAs. J Virol, 62, 206-
210. 
126. Samulski, R. J., Zhu, X., Xiao, X., Brook, J. D., Housman, D. E., Epstein, N. and Hunter, 
L. A. (1991) Targeted integration of adeno-associated virus (AAV) into human 
chromosome 19. EMBO J, 10, 3941-3950. 
127. Schappert-Kimmijser, J., Henkes, H. E. and Van Den Bosch, J. (1959) Amaurosis 
congenita (Leber). AMA Arch Ophthalmol, 61, 211-218. 
128. Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A. and Johnson, P. R. (2003) 
Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol, 
77, 3495-3504. 
129. Schroeder, R., Mets, M. B. and Maumenee, I. H. (1987) Leber's congenital amaurosis. 
Retrospective review of 43 cases and a new fundus finding in two cases. Arch 
Ophthalmol, 105, 356-359. 
130. Schultz, B. R. and Chamberlain, J. S. (2008) Recombinant adeno-associated virus 
transduction and integration. Mol Ther, 16, 1189-1199. 
131. Simonelli, F., Maguire, A. M., Testa, F., Pierce, E. A., Mingozzi, F., Bennicelli, J. L., 
Rossi, S., Marshall, K., Banfi, S., Surace, E. M. et al. (2010) Gene therapy for Leber's 
127 
 
congenital amaurosis is safe and effective through 1.5 years after vector administration. 
Mol Ther, 18, 643-650. 
132. Simonelli, F., Ziviello, C., Testa, F., Rossi, S., Fazzi, E., Bianchi, P. E., Fossarello, M., 
Signorini, S., Bertone, C., Galantuomo, S. et al. (2007) Clinical and molecular genetics of 
Leber's congenital amaurosis: a multicenter study of Italian patients. Invest Ophthalmol 
Vis Sci, 48, 4284-4290. 
133. Sohocki, M. M., Bowne, S. J., Sullivan, L. S., Blackshaw, S., Cepko, C. L., Payne, A. M., 
Bhattacharya, S. S., Khaliq, S., Qasim Mehdi, S., Birch, D. G. et al. (2000a) Mutations in 
a new photoreceptor-pineal gene on 17p cause Leber congenital amaurosis. Nat Genet, 
24, 79-83. 
134. Sohocki, M. M., Perrault, I., Leroy, B. P., Payne, A. M., Dharmaraj, S., Bhattacharya, S. 
S., Kaplan, J., Maumenee, I. H., Koenekoop, R., Meire, F. M. et al. (2000b) Prevalence 
of AIPL1 mutations in inherited retinal degenerative disease. Mol Genet Metab, 70, 142-
150. 
135. Sprecher-Goldberger, S., Thiry, L., Lefebvre, N., Dekegel, D. and de Halleux, F. (1971) 
Complement-fixation antibodies to adenovirus-associated viruses, cytomegaloviruses and 
herpes simplex viruses in patients with tumors and in control individuals. Am J 
Epidemiol, 94, 351-358. 
136. Summerford, C. and Samulski, R. J. (1998) Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 72, 1438-
1445. 
137. Sun, X., Pawlyk, B., Xu, X., Liu, X., Bulgakov, O. V., Adamian, M., Sandberg, M. A., 
Khani, S. C., Tan, M. H., Smith, A. J. et al. (2010) Gene therapy with a promoter 
targeting both rods and cones rescues retinal degeneration caused by AIPL1 mutations. 
Gene Ther, 17, 117-131. 
138. Tan, M. H., Smith, A. J., Pawlyk, B., Xu, X., Liu, X., Bainbridge, J. B., Basche, M., 
McIntosh, J., Tran, H. V., Nathwani, A. et al. (2009) Gene therapy for retinitis 
pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue 
of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 
vectors. Hum Mol Genet, 18, 2099-2114. 
139. Testa, F., Surace, E. M., Rossi, S., Marrocco, E., Gargiulo, A., Di Iorio, V., Ziviello, C., 
Nesti, A., Fecarotta, S., Bacci, M. L. et al. (2011) Evaluation of Italian Patients with 
Leber Congenital Amaurosis due to AIPL1 Mutations Highlights the Potential 
Applicability of Gene Therapy. Invest Ophthalmol Vis Sci. 
140. Umino, Y., Frio, B., Abbasi, M. and Barlow, R. (2006) A two-alternative, forced choice 
method for assessing mouse vision. Adv Exp Med Biol, 572, 169-172. 
141. Umino, Y., Solessio, E. and Barlow, R. B. (2008) Speed, spatial, and temporal tuning of 
rod and cone vision in mouse. J Neurosci, 28, 189-198. 
142. Vallespin, E., Cantalapiedra, D., Riveiro-Alvarez, R., Wilke, R., Aguirre-Lamban, J., 
Avila-Fernandez, A., Lopez-Martinez, M. A., Gimenez, A., Trujillo-Tiebas, M. J., 
Ramos, C. et al. (2007) Mutation screening of 299 Spanish families with retinal 
dystrophies by Leber congenital amaurosis genotyping microarray. Invest Ophthalmol Vis 
Sci, 48, 5653-5661. 
143. van der Spuy, J., Kim, J. H., Yu, Y. S., Szel, A., Luthert, P. J., Clark, B. J. and Cheetham, 
M. E. (2003) The expression of the Leber congenital amaurosis protein AIPL1 coincides 
with rod and cone photoreceptor development. Invest Ophthalmol Vis Sci, 44, 5396-5403. 
128 
 
144. Veske, A., Nilsson, S. E., Narfstrom, K. and Gal, A. (1999) Retinal dystrophy of Swedish 
briard/briard-beagle dogs is due to a 4-bp deletion in RPE65. Genomics, 57, 57-61. 
145. Walia, S., Fishman, G. A., Jacobson, S. G., Aleman, T. S., Koenekoop, R. K., Traboulsi, 
E. I., Weleber, R. G., Pennesi, M. E., Heon, E., Drack, A. et al. (2010) Visual acuity in 
patients with Leber's congenital amaurosis and early childhood-onset retinitis 
pigmentosa. Ophthalmology, 117, 1190-1198. 
146. Walters, R. W., Yi, S. M., Keshavjee, S., Brown, K. E., Welsh, M. J., Chiorini, J. A. and 
Zabner, J. (2001) Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is 
required for gene transfer. J Biol Chem, 276, 20610-20616. 
147. Weitzman, M. D., Kyostio, S. R., Kotin, R. M. and Owens, R. A. (1994) Adeno-
associated virus (AAV) Rep proteins mediate complex formation between AAV DNA 
and its integration site in human DNA. Proc Natl Acad Sci U S A, 91, 5808-5812. 
148. Wert, K. J., Davis, R. J., Sancho-Pelluz, J., Nishina, P. M. and Tsang, S. H. (2012) Gene 
Therapy Provides Long-term Visual Function in a Pre-clinical Model of Retinitis 
Pigmentosa. Hum Mol Genet. 
149. Wright, A. F. (1997) Gene therapy for the eye. Br J Ophthalmol, 81, 620-623. 
150. Wright, A. F., Chakarova, C. F., Abd El-Aziz, M. M. and Bhattacharya, S. S. (2010) 
Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat 
Rev Genet, 11, 273-284. 
151. Wrigstad, A., Narfstrom, K. and Nilsson, S. E. (1994) Slowly progressive changes of the 
retina and retinal pigment epithelium in Briard dogs with hereditary retinal dystrophy. A 
morphological study. Doc Ophthalmol, 87, 337-354. 
152. Wrigstad, A., Nilsson, S. E. and Narfstrom, K. (1992) Ultrastructural changes of the 
retina and the retinal pigment epithelium in Briard dogs with hereditary congenital night 
blindness and partial day blindness. Exp Eye Res, 55, 805-818. 
153. Wu, J., Zhao, W., Zhong, L., Han, Z., Li, B., Ma, W., Weigel-Kelley, K. A., Warrington, 
K. H. and Srivastava, A. (2007) Self-complementary recombinant adeno-associated viral 
vectors: packaging capacity and the role of rep proteins in vector purity. Hum Gene Ther, 
18, 171-182. 
154. Wu, Z., Yang, H. and Colosi, P. (2010) Effect of genome size on AAV vector packaging. 
Mol Ther, 18, 80-86. 
155. Xiao, X., Li, J. and Samulski, R. J. (1998) Production of high-titer recombinant adeno-
associated virus vectors in the absence of helper adenovirus. J Virol, 72, 2224-2232. 
156. Yan, Z., Zak, R., Luxton, G. W., Ritchie, T. C., Bantel-Schaal, U. and Engelhardt, J. F. 
(2002) Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects 
the transduction efficiency of recombinant vectors. J Virol, 76, 2043-2053. 
157. Yang, G. S., Schmidt, M., Yan, Z., Lindbloom, J. D., Harding, T. C., Donahue, B. A., 
Engelhardt, J. F., Kotin, R. and Davidson, B. L. (2002) Virus-mediated transduction of 
murine retina with adeno-associated virus: effects of viral capsid and genome size. J 
Virol, 76, 7651-7660. 
158. Yin, L., Greenberg, K., Hunter, J. J., Dalkara, D., Kolstad, K. D., Masella, B. D., Wolfe, 
R., Visel, M., Stone, D., Libby, R. T. et al. (2011) Intravitreal injection of AAV2 
transduces macaque inner retina. Invest Ophthalmol Vis Sci, 52, 2775-2783. 
159. Yokoi, K., Kachi, S., Zhang, H. S., Gregory, P. D., Spratt, S. K., Samulski, R. J. and 
Campochiaro, P. A. (2007) Ocular gene transfer with self-complementary AAV vectors. 
Invest Ophthalmol Vis Sci, 48, 3324-3328. 
129 
 
160. Young, J. E., Gross, K. W. and Khani, S. C. (2005) Conserved structure and 
spatiotemporal function of the compact rhodopsin kinase (GRK1) enhancer/promoter. 
Mol Vis, 11, 1041-1051. 
161. Young, J. E., Vogt, T., Gross, K. W. and Khani, S. C. (2003) A short, highly active 
photoreceptor-specific enhancer/promoter region upstream of the human rhodopsin 
kinase gene. Invest Ophthalmol Vis Sci, 44, 4076-4085. 
162. Zhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, 
M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S. et al. (2008a) 
Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular 
trafficking and transgene expression. Virology, 381, 194-202. 
163. Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., 
Herzog, R. W., Zolotukhin, I., Warrington, K. H., Jr., Weigel-Van Aken, K. A. et al. 
(2008b) Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines 
lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A, 105, 7827-
7832. 
164. Zhong, L., Zhao, W., Wu, J., Li, B., Zolotukhin, S., Govindasamy, L., Agbandje-
McKenna, M. and Srivastava, A. (2007) A dual role of EGFR protein tyrosine kinase 
signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol 
Ther, 15, 1323-1330. 
165. Zolotukhin, S., Byrne, B. J., Mason, E., Zolotukhin, I., Potter, M., Chesnut, K., 
Summerford, C., Samulski, R. J. and Muzyczka, N. (1999) Recombinant adeno-
associated virus purification using novel methods improves infectious titer and yield. 
Gene Ther, 6, 973-985. 
166. Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Jr., Chiodo, 
V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W. et al. (2002) Production and 
purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods, 
28, 158-167. 
 
 
